

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/74837 A1

(51) International Patent Classification⁷: **C07H 21/04**,
C12N 9/12, 15/63, 5/00, 5/04, 5/06, 1/20, 1/16, C12P
21/06, C12Q 1/48, G01N 33/53, A61K 38/45, 39/395,
31/70

(21) International Application Number: PCT/US01/09664

(22) International Filing Date: 26 March 2001 (26.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/194,318 3 April 2000 (03.04.2000) US
09/817,676 26 March 2001 (26.03.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE
(utility model), DK, DK (utility model), DM, DZ, EE, EE
(utility model), ES, FI, FI (utility model), GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants: **SANKYO COMPANY, LIMITED** [JP/JP];
5-1, Nihonbashi Honcho 3-chome, Chuo-ku, Tokyo 103
(JP). **GEORGETOWN UNIVERSITY** [US/US]; 37th &
"O" Streets, N.W., Washington, DC 20057 (US).

(71) Applicants and

(72) Inventors: **SPIEGEL, Sarah** [US/US]; 6343 Linway
Terrace, McLean, VA 22101 (US). **KOHAMA, Taka-
fumi** [JP/JP]; 1-4-5-614, Motomachi, Kiyose-shi, Tokyo
204-0021 (JP).

(74) Agents: **BARTH, Richard, S.** et al.; Frishauf, Holtz,
Goodman, Langer & Chick, P.C., 767 Third Avenue, New
York, NY 10017-2023 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MAMMALIAN SPHINGOSINE KINASE TYPE 2 ISOFORMS, CLONING, EXPRESSION AND METHODS OF USE
THEREOF

(57) Abstract: Nucleic acids encoding mouse and human sphingosine kinase type 2 isoforms, methods for detecting agents or drugs
which inhibit or promote sphingosine activity and therapeutic agents containing peptides or antibodies to peptides encoded by such
nucleic acids.



WO 01/74837 A1

**MAMMALIAN SPHINGOSINE KINASE TYPE 2 ISOFORMS,
CLONING, EXPRESSION AND METHODS OF USE THEREOF**

CROSS-REFERENCE TO RELATED APPLICATION

The present application claims the benefit of Provisional Application Serial No. 60/194,318, filed April 3, 2000, wherein priority under 35 USC 119(e) is claimed.

GOVERNMENT RIGHTS

This invention was made with United States government support under Grant GM 43880 from the National Institutes of Health and a Postdoctoral Fellowship BC961968 from the United States Army Medical Research and Materiel Command, Prostate Cancer Research Program (VEN). The United States government has certain rights in this invention.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention concerns mammalian (such as mouse and human) sphingosine kinase type 2 isoforms, the molecular cloning of such isoforms and methods of use of such isoforms. Sphingosine kinase type 2 has distinct characteristics when compared to sphingosine kinase type 1.

Background Information

Sphingosine-1-phosphate (SPP) is a bioactive sphingolipid metabolite which regulates diverse biological processes acting both inside cells as a second messenger to regulate proliferation and survival and outside cells as a ligand for G-protein coupled receptors of the EDG-1 subfamily (Spiegel, S., *J. Leukoc. Biol.*, **65**, (1999), 341-344; Goetzl, E.J., An, S., *FASEB J.*, **12**, (1998), 1589-1598). Thus, SPP plays important roles as a second messenger to regulate cell growth and survival (Olivera, A., Spiegel, S., *Nature*, **365**, (1993), 557-560; Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coso, O. A., Gutkind, S., and Spiegel, S., *Nature*, **381**, (1996), 800-803).

Many external stimuli, particularly growth and survival factors, activate sphingosine kinase ("SPHK"), the enzyme that forms SPP from sphingosine. This rapidly growing list includes platelet-derived growth factor ("PDGF") (Olivera, A., Spiegel, S., Nature, 365, (1993), 557-560; Pyne, S., Chapman, J. Steele, L., and Pyne, N.J., Eur. J. Biochem., 237, (1996), 819-826; Coroneos, E., Martinez, M., McKenna, S. and Kester, M., J. Biol. Chem., 270, (1995), 23305-23309), nerve growth factor ("NGF") (Edsall, L. C., Pirianov, G. G., and Spiegel, S., J. Neurosci., 17, (1997), 6952-6960; Rius, R.A., Edsall, L.C., and Spiegel, S., FEBS Lett., 417, (1997), 173-176), vitamin D3 (Kleuser, B., Cuvillier, O., and Spiegel, S., Cancer Res., 58, (1998) 1817-1824), muscarinic acetylcholine agonists (Meyer zu Heringdorf, D., Lass, H., Alemany, R., Laser, K.T., Neumann, E. Zhang, C., Schmidt, M., Rauen, U., Jakobs, K.H., and van Koppen, C.J., EMBO J., 17, (1998), 2830-2837), TNF- α (Xia, P., Gamble, J.R., Rye, K.A., Wang, L., Hii, C.S.T., Cockerill, P., Khew-Goodall, Y., Bert, A.G., Barter, P.J., and Vadas, M.A., Proc. Natl. Acad. Sci. USA, 95, (1998), 14196-14201), and the cross-linking of the immunoglobulin receptors Fc ϵ R1 (Choi, O. H., Kim, J.-H., and Kinet, J.-P., Nature, 380, (1996), 634-636) and Fc γ R1 (Melendez, A., Floto, R. A., Gillooly, D. J., Harnett, M. M., and Allen, J.M., J. Biol. Chem., 273 (1998), 9393-9402).

Intracellular SPP, in turn, mobilizes calcium from internal stores independently of InsP3 (Meyer zu Heringdorf, D., Lass, H., Alemany, R., Laser, K.T., Neumann, E. Zhang, C., Schmidt, M., Rauen, U., Jakobs, K.H., and van Koppen, C.J., EMBO J., 17, (1998), 2830-2837; Mattie, M., Brooker, G, and Spiegel, S., Biol. Chem., 269, (1994), 3181-3188), as well as eliciting diverse signaling pathways leading to proliferation (Rani, C.S., Berger, A., Wu, J., Sturgill, T. W., Beitner-Johnson, D., LeRoith, D., Varticovski, L., and Spiegel, S., J. Biol. Chem., 272, (1997), 10777-10783; Van Brocklyn, J. R., Lee, M. J., Menzeleev, R, Olivera, A., Edsall, L., Cuvillier,

O., Thomas, D. M., Coopman, P. J. P., Thangada, S., Hla, T., and Spiegel, S., J. Cell Biol., **142**, (1998), 229-240) and suppression of apoptosis (Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coso, O. A., Gutkind, S., and Spiegel, S., Nature, **381**, (1996), 800-803; Edsall, L. C., Pirianov, G. G., and Spiegel, S., J. Neurosci., **17**, (1997), 6952-6960; Van Brocklyn, J.R., Lee, M. J., Menzeleev, R., Olivera, A., Edsall, L., Cuvillier, O., Thomas, D. M., Coopman, P. J. P., Thangada, S., Hla, T., and Spiegel S., J. Cell Biol., **142**, (1998), 229-240).

Moreover, competitive inhibitors of sphingosine kinase block formation of SPP and selectively inhibit calcium mobilization, cellular proliferation and survival induced by these various stimuli (Spiegel, S., J. Leukoc. Biol., **65**, (1999), 341-344). Thus, it has been suggested that the dynamic balance between levels of the sphingolipid metabolites, ceramide and SPP, and the consequent regulation of opposing signaling pathways, is an important factor that determines the fate of cells (Cuvillier, O., Rosenthal, D. S., Smulson, M. E., and Spiegel, S., J. Biol. Chem., **273**, (1998), 2910-2916). For example, stress stimuli increase ceramide levels leading to apoptosis, whereas survival factors stimulate SPHK leading to increased SPP levels, which suppress apoptosis (Cuvillier, O., Rosenthal, D. S., Smulson, M. E., and Spiegel, S., J. Biol. Chem., **273**, (1998), 2910-2916).

Furthermore, the SPHK pathway, through the generation of SPP, is critically involved in mediating TNF- α -induced endothelial cell activation (Xia, P., Gamble, J.R., Rye, K.A., Wang, L., Hii, C.S.T., Cockerill, P., Khew-Goodall, Y., Bert, A.G., Barter, P.J., and Vadas, M.A., Proc. Natl. Acad. Sci. USA, **95**, (1998), 14196-14201) and the ability of high density lipoproteins (HDL) to inhibit cytokine-induced adhesion molecule expression has been correlated with its ability to reset this sphingolipid rheostat (Xia, P., Gamble, J.R., Rye, K.A., Wang, L., Hii, C.S.T., Cockerill, P., Khew-Goodall, Y.,

Bert, A.G., Barter, P.J., and Vadas, M.A., Proc. Natl. Acad. Sci. USA, 95, (1998), 14196-14201). This has important implications for the protective function of HDL against the development of atherosclerosis and associated coronary heart disease. Recent data has also connected the sphingolipid rheostat to allergic responses (Prieschl, E., E., Csonga, R., Novotny, V., Kikuchi, G. E., and Baumruker, T., J. Exp. Med., 190, (1999), 1-8).

Interest in SPP has accelerated recently with the discovery that it is a ligand of the G-protein coupled cell surface receptor EDG-1 (Van Brocklyn, J. R., Lee, M. J., Menzeleev, R., Olivera, A., Edsall, L., Cuvillier, O., Thomas, D. M., Coopman, P. J. P., Thangada, S., Hla, T., and Spiegel, S., J. Cell Biol., 142, (1998), 229-240; Lee, M. J., Van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S., and Hla, T., Science, 279, (1998), 1552-1555). This rapidly led to the identification of several other related receptors, named EDG-3, -5, -6, and -8, which are also specific SPP receptors (Goetzl, E. J., and An, S., FASEB J., 12, (1998), 1589-1598; Spiegel, S., and Milstein, S., Biochem. Biophys. Acta., 1484(2-3):107-16, (2000)).

Sphinganine-1-phosphate, which is structurally similar to SPP and lacks only the trans double bond at the 4-position, but not lysophosphatidic acid or sphingosylphosphorylcholine, also binds to these receptors (Van Brocklyn, J. R., Tu, Z., Edsall, L. C., Schmidt, R. R., and Spiegel, S., J. Biol. Chem., 274, (1999) 4626-4632), demonstrating that EDG-1 belongs to a family of G-protein coupled receptors that bind SPP with high affinity and specificity (Goetzl, E. J. and An, S., FASEB J., 12, (1998), 1589-1598; Spiegel, S. and Milstien, S., Biochem. Biophys. Acta., 1484(2-3):107-16, (2000)).

The EDG-1 family of receptors are differentially expressed, mainly in the cardiovascular and nervous systems, and are coupled to a variety of G-proteins and thus can regulate diverse signal transduction pathways culminating in

pleiotropic responses depending on the cell type and relative expression of EDG receptors. Although the biological functions of the EDG-1 family of GPCRs are not completely understood, recent studies suggest that binding of SPP to EDG-1 stimulates migration and chemotaxis (Wang, F., Van Brocklyn, J. R., Hobson, J. P., Movafagh, S., Zukowska-Grojec, Z., Milstien, S., and Spiegel, S. J. Biol. Chem., 274, (1999), 35343-35350; English, D., Kovala, A. T., Welch, Z., Harvey, K. A., Siddiqui, R. A., Brindley, D. N., and Garcia, J. G., J. Hematother. Stem Cell Res., 8, (1999), 627-634), and as a consequence, may regulate angiogenesis (Wang, F., Van Brocklyn, J. R., Hobson, J. P., Movafagh, S., Zukowska-Grojec, Z., Milstien, S., and Spiegel, S. J. Biol. Chem., 274, (1999), 35343-35350; Lee, O. H., Kim, Y. M., Lee, Y. M., Moon, E. J., Lee, D. J., Kim, J. H., Kim, K. W., and Kwon, Y. G., Biochem. Biophys. Res. Commun., 264, (1999) 743-750; Lee, M. J., Thangada, S., Claffey, K. P., Ancellini, N., Liu, C. H., Kluk, M., Volpi, Sha'afi, R. I., and Hla, T., Cell, 99, (1999), 301-312). EDG-5 may play a role in cytoskeletal reorganization during neurite retraction, which is important for neuronal differentiation and development (Van Brocklyn, J. R., Tu, Z., Edsall, L. C., Schmidt, R. R., and Spiegel, S., J. Biol. Chem., 274, (1999), 4626-4632; MacLennan, A. J., Marks, L., Gaskin, A. A., and Lee, N., Neuroscience, 79, (1997), 217-224).

Critical evaluation of the role of SPP requires cloning of the enzymes that regulate its metabolism. Recently, rat kidney SPHK has been purified to apparent homogeneity (Olivera, A., Kohama, T., Tu, Z., Milstien, S., and Spiegel, S., J. Biol. Chem., 273, (1998), 12576-12583) and subsequently the first mammalian SPHK, designated mSPHK1 (Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S., J. Biol. Chem., 273, (1998), 23722-23728) was cloned. Independently, two genes, termed LCB4 and LCB5, were also shown to code for SPHKs in *Saccharomyces cerevisiae* (Nagiec, M. M., Skrzypek, M., Nagiec, E. E., Lester, R. L., and Dickson, R. C.,

J. Biol. Chem., 273, (1998) 19437-19442). Moreover, databases identify homologues of mSPHK1 in numerous widely disparate organisms, including worms, plants and mammals, demonstrating that the enzyme is encoded by a member of a highly conserved gene family (Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S., J. Biol. Chem., 273, (1998), 23722-23728). Comparison of the predicted amino acid sequences of the known SPHK1s revealed five blocks of highly conserved amino acids (Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S., J. Biol. Chem., 273, (1998), 23722-23728). However, several lines of evidence indicate that there may be multiple mammalian SPHK isoforms.

The finding that SPHK activity in platelets could be chromatographically fractionated into several forms with differing responses to detergents and inhibition by known SPHK inhibitors, indicate the presence of multiple enzyme forms in human platelets (Banno, Y., Kato, M., Hara, A., and Nozawa, Y., Biochem. J., 335, (1998), 301-304). Moreover, homology searches against a comprehensive nonredundant database revealed that several of the expressed sequence tags (dbEST) at NCBI had significant homology to conserved domains of mSPHK1a (Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S., J. Biol. Chem., 273, (1998), 23722-23728), yet had substantial sequence differences.

USP 5,374,616 concerns compositions containing sphingosylphosphorylcholine for promoting cellular proliferation of mammalian cells.

WO 99/61581 describes DNA fragments which encoded murine sphingosine SPHK1a (381 amino acids) and SPHK1b (388 amino acids).

SUMMARY OF THE INVENTION

It is an object of the present invention to provide isolated and purified DNAs which encode mammalian (such as a mouse or human) sphingosine kinase type 2 isoforms and peptides

encoded therefrom.

It is a further object of the present invention to provide recombinant DNA constructs comprising a vector and the above described DNAs and host cells transformed with such recombinant DNA constructs.

It is a still further object of the present invention to furnish a method for producing mouse and human sphingosine type 2 isoform peptides by culturing such host cells.

It is an additional object of the present invention to provide a method for detecting an agent or a drug which inhibits or promotes sphingosine kinase activity.

It is yet another object of the present invention to provide a method for regulating a biological process; for treating or ameliorating a disease resulting from increased or decreased cell proliferation or increased or decreased cell death; and for treating or ameliorating a disease resulting from abnormal migration or motility of cells such as cancer, restenosis or diabetic neuropathy.

The present invention is also directed to an isolated and purified DNA which encodes a peptide of a sphingosine kinase type 2 isoform, the DNA comprising a sequence selected from the group consisting of the sequence of Genbank Accession No. bankit325787 and the sequence of Genbank Accession No. bankit325752.

The present invention also concerns methods for detecting an agent or a drug which inhibits or promotes sphingosine kinase type 2 activity comprising:

- (a) providing a recombinant DNA construct as discussed above, into a cell such that sphingosine kinase type 2 isoform is produced in the cell;
- (b) adding at least one drug or agent to the cell, and
- (c) detecting whether or not the drug or agent inhibits or promotes sphingosine kinase type 2 activity by measuring sphingosine kinase-dependent phosphorylation of lipids in the cells and comparing the resultant measurement to a control

which did not receive the drug or agent, wherein a decrease in the amount of sphingosine kinase-dependent phosphorylation of lipids as compared to the control indicates an inhibitory drug or agent, or an increase in the amount of sphingosine kinase-dependent phosphorylation of lipids in the cell as compared to the control indicates a stimulatory drug or agent.

As described hereinabove, the present invention also relates to methods of regulating a biological process (such as mitogenesis, apoptosis, neuronal development, chemotaxis, angiogenesis and inflammatory responses) in a mammal comprising administering to a mammal (such as a human) in need thereof, a pharmaceutically effective amount of a peptide as described above.

Also as described hereinabove, the present invention is further directed to methods for the treatment or amelioration of a disease resulting from increased cell death or decreased cell proliferation, comprising administering to a mammal (such as a human) in need thereof, a pharmaceutically effective amount of a peptide as described above.

Further as described above, the present invention also relates to methods for the treatment or administration of a disease resulting from decreased cell death or increased cell proliferation comprising administering to a mammal (such as a human) in need thereof, a pharmaceutically effective amount of an antibody to a peptide as described above.

Additionally as described above, the present invention further concerns methods for treatment or amelioration of a disease resulting from abnormal migration or motility of cells selected from the group consisting of cancer, restenosis and diabetic neuropathy, the method comprising administering to a mammal (such as a human) in need thereof, a pharmaceutically effective amount of an antibody to a peptide as described above.

The present invention further relates to compositions for (a) regulating biological processes, (b) treating or

ameliorating diseases resulting from increased cell death or decreased cell proliferation, (c) treating or ameliorating diseases resulting from decreased cell death or increased cell proliferation, or (d) treating or ameliorating diseases resulting from abnormal migration or motility of cells (such as cancer, restenosis and diabetic neuropathy) comprising (i) a pharmaceutically effective amount of a peptide as described above or an antibody to such peptide as described above, and (ii) a pharmaceutically acceptable carrier.

The present invention also involves a method for screening agents or drugs which reduce or eliminate sphingosine kinase type 2 activity, the method comprising detecting a decrease in sphingosine kinase type 2 enzyme activity in the presence of the agent or drug.

Furthermore, the present invention is directed to a method for detecting the presence of sphingosine kinase type 2 isoform in a sample comprising:

(i) contacting a sample with antibodies which recognize sphingosine kinase type 2; and

(ii) detecting the presence or absence of a complex formed between sphingosine kinase type 2 and antibodies specific therefor.

The present invention also concerns a method for detecting sphingosine kinase type 2 in a sample comprising subjecting the sample to a polymerase chain reaction and detecting for the presence of sphingosine kinase type 2.

The present invention is additionally directed to a diagnostic kit for detecting sphingosine kinase type 2 RNA/cDNA in a sample comprising primers or oligonucleotides specific for sphingosine kinase type 2 RNA or cDNA suitable for hybridization to sphingosine kinase type 2 RNA or cDNA and/or amplification of sphingosine kinase type 2 sequences and suitable ancillary reagents.

Sphingosine kinase catalyzes the phosphorylation of sphingosine to yield SPP. Based on sequence homology to murine

and human sphingosine kinase-1 (SPHK1), which was recently cloned (Kohama, et al., J. Biol. Chem., 273, 23722-23728, (1998)), the present invention is directed to the cloning, functional characterization, and tissue distribution of a second type of mouse and human sphingosine kinase (mSPHK2 and hSPHK2).

mSPHK2 and hSPHK2 of the present invention encode proteins of 617 and 618 amino acids, respectively, both much larger than SPHK1, and both contain the conserved domains previously found in SPHK1, but their sequences diverge considerably in the centers and at the amino termini. Northern blot analysis of multiple human and murine tissues revealed that SPHK2 mRNA expression was strikingly different from that of SPHK1 and was highest in brain, heart, kidney, testes, and liver. Whereas SPHK1 expression is greatest at mouse embryonic day 7, SPHK2 expression is only detectable at embryonic day 11 and increases thereafter.

Human embryonic 293 kidney cells transiently transfected with mSPHK2 or hSPHK2 expression vectors had marked increases in SPHK activity resulting in elevated SPP levels. Notably, SPHK2 had somewhat different substrate specificity than SPHK1. D-erythro-sphinganine (dihydrosphingosine, DHS) was an even better substrate than D-erythro-sphingosine for SPHK2, while DHS was a potent inhibitor of SPHK1.

SPHK2 also catalyzed the phosphorylation of phytosphingosine and D, L-threo-dihydrosphingosine, albeit to a lesser extent. DMS, a competitive inhibitor of SPHK1, surprisingly was a non-competitive inhibitor of SPHK2. Although increasing ionic strength inhibited SPHK1, KCl and NaCl markedly stimulated SPHK2 activity. Moreover, Triton X-100 and BSA inhibited SPHK2, in contrast to their effects on SPHK1, whereas phosphatidylserine stimulated both types. The data herein indicate that SPHK2 is a novel member of this growing class of lipid kinases, which is important in the regulation of diverse biological processes, including

mitogenesis, apoptosis, neuronal development, chemotaxis, angiogenesis, and inflammatory responses.

BRIEF DESCRIPTION OF THE DRAWINGS

For the purposes of illustrating the invention, features, aspects and advantages are shown in the drawings. It is to be understood, however, that the present invention is not limited to that which is depicted in the drawings

Fig. 1A shows predicted amino acid sequences of murine and human type 2 sphingosine kinase based on non-ClustalW alignment of the predicted amino acid sequences of ("mSPHK2") and human sphingosine kinase 2 ("hSPHK2"). Identical and conserved amino acid substitutions are shaded dark and light gray, respectively. The dashes represent gaps in sequences and numbers on the right refer to the amino acid sequence of mSPHK2. The conserved domains (C1 to C5) are indicated by lines.

Fig. 1B is a schematic representation of conserved regions of SPHK1 and SPHK2. The primary sequence of mSPHK2 is compared to that of mSPHK1a.

Figs. 2A, 2B and 2C are Northern blots which show the tissue specific expression of type 1 and type 2 sphingosine kinase.

In Fig. 2A, mSPHK2 (upper panel) and mSPHK1a (middle panel) probes were end labeled and hybridized to poly(A)+ RNA blots from the indicated mouse tissues as described hereinbelow. Lanes: 1, heart; 2, brain; 3, spleen; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, testis. A β -actin probe (lower panel) was used as a loading control.

Fig. 2B shows the tissue specific expression of hSPHK2. Lanes 1, brain; 2, heart; 3, skeletal muscle; 4, colon; 5, thymus; 6, spleen; 7, kidney; 8, liver; 9, small intestine; 10, placenta; 11, lung; 12, leukocyte.

Fig. 2C shows the expression of mSPHK1a and mSPHK2 during mouse embryonic development. Poly(A)+ RNA blots from days 7,

11, 15 and 17 mouse embryos were probed as in Fig. 2A.

Figs. 3A and 3B are graphs which show the enzymatic activity of recombinant SPHK2.

In Fig. 3A, HEK 293 cells were transiently transfected with an empty vector or with mSPHK2 or hSPHK2 expression vectors. After 24 hours, SPHK activity was measured in cytosol (open bars) and particulate fractions (filled bars). The data are means \pm S.D. Parental and vector-transfected cells had basal SPHK activities of 26 and 37 pmol/min/mg, respectively.

Fig. 3B shows the changes in mass levels of SPP after transfection with SPHK2. Mass levels of SPP in HEK293 cells transfected with an empty vector (open bars) or with mSPHK2 (filled bars) or with hSPHK2 (hatched bars) were measured as described hereinbelow. The data are expressed as pmol/nmol phospholipid.

Figs. 4A to 4D are graphs which show the substrate specificity of mSPHK2.

Fig. 4A is a graph which shows SPHK-dependent phosphorylation of various sphingosine analogs or other lipids (50 mM) which was measured in cytosol from HEK293 cells transfected with mSPHK2. Lanes: 1, D-erythro-sphingosine ("D-erythro-Sph"); 2, D-erythro-dihydrosphingosine ("D-erythro-DHS"); 3, D, L-threo-DHS; 4, N,N-dimethylsphingosine ("DMS"); 5, C2-ceramide; 6, C16-ceramide; 7, diacylglycerol; 8, phosphatidylinositol; 9, phytosphingosine. Data are expressed as percentage of phosphorylation of D-erythro-Sph.

Figs. 4A to 4D are graphs which show the noncompetitive inhibition of recombinant SPHK2 by N,N-dimethylsphingosine.

Fig. 4B shows the dose-dependent inhibition of mSPHK2 by DMS. SPHK activity in HEK293 cell lysates after transfection as in Fig. 4A was measured with 10 μ M D-erythro-sphingosine in the presence of increasing concentrations of DMS.

Fig. 4C shows a kinetic analysis of DMS inhibition. SPHK activity was measured with varying concentrations of D-erythro-sphingosine in the absence (open circles) or presence of 10 μ M (filled squares) or 20 μ M DMS (filled triangles).

Fig. 4D are Lineweaver-Burk plots. The K_m for D-erythro-sphingosine was 3.4 μ M. The K_i value for DMS was 12 μ M.

Figs. 5A to 5E are graphs which show the pH dependence and salt effects on mSPHK2.

Fig. 5A shows cytosolic SPHK2 activity in transfected HEK 293 cells that was measured in a kinase buffer with the pH adjusted using the following buffers: 200 mM sodium acetate (pH 4.5-5.5, open circles); 200 mM MES (pH 6-7, filled circles); 200 mM potassium phosphate (pH 6.5-8, open squares); 200 mM HEPES (pH 7-7.5, filled squares); 200 mM Tris-HCl (pH 7.5-9, open triangles); and 200 mM borate (pH 10, filled triangle).

Figs. 5B to 5E show that salts stimulate SPHK2, but inhibit SPHK1.

In Figs. 5B and 5C, the SPHK activity in HEK293 cell lysates was measured 24 hours after transfection with mSPHK1 (Fig. 5B) or mSPHK2 (Fig. 5C) in the absence or presence of increasing concentrations of NaCl (open squares) or KCl (filled circles).

Fig. 5D shows a kinetic analysis of SPHK2 activation by KCl. mSPHK2 activity was measured with varying concentrations of D-erythro-sphingosine in the absence (open circles), or presence of 50 mM KCl (open squares), or 200 mM KCl (filled squares).

Fig. 5E are Lineweaver-Burk plots of data from Fig 5D. The K_m value not affected by the presence of KCl. V_{max} values were 0.1, 0.3 and 1 (nmol/min/mg) in the presence of 0, 50, and 200 mM KCl, respectively.

Figs. 6A to 6B are graphs which show that Triton X-100 and bovine serum albumin ("BSA") have differential effects on the activity of SPHK1 and SPHK2. HEK293 cells were transfected

with mSPHK1a (open circles) or mSPHK2 (filled circles) and the activities of each in cell lysates were measured after 24 hours in the presence of the indicated concentrations of Triton X-100 (Fig. 6A) or BSA (Fig. 6B).

Fig. 6C is a graph which shows that phosphatidylserine has similar effects on the activity of SPHK1 and SPHK2. HEK293 cells were transfected with mSPHK1a (circles) or mSPHK2 (triangles) and the activities of each in cell lysates were measured after 24 hours in the presence of the indicated concentrations of phosphatidylserine (filled symbols) or phosphatidylcholine (open symbols). Data are expressed as percentage of control activity measured without any additions.

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, the present invention relates to a DNA or cDNA segment which encodes mammalian (such as mouse and human) sphingosine kinase type 2 isoforms.

In addition, isolated nucleic acid molecules of the invention include DNA molecules which comprise sequences substantially different from those described above but which, due to the degeneracy of the genetic code, still encode mammalian sphingosine kinase type 2 isoforms. Of course, the genetic code and species-specific codon preferences are well known in the art. Thus, it would be routine for one of ordinary skill in the art to generate the degenerate variants described above, for instance, to optimize codon expression for a particular host (e.g., change codons in the human mRNA to those preferred by a bacterial host such as *E.coli*).

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the "sense strand", or it may be the noncoding strand, also referred to as the

"antisense strand".

By "isolated" nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

The present invention is further directed to nucleic acid molecules encoding portions or fragments of the nucleotide sequences described herein. Fragments include portions of the nucleotide sequences of Fig. 1A for mSPHK2 and hSPHK2 at least 10 contiguous nucleotides in length selected from any two integers, one of which 5 representing a 5' nucleotide position and a second of which representing a 3' nucleotide position, where the first nucleotide for each nucleotide sequence in Fig. 1A is position 1. That is, every combination of a 5' and 3' nucleotide position that a fragment at least 10 contiguous nucleotide bases in length or any integer between 10 and the length of an entire nucleotide sequence of mSPHK2 or hSPHK2 of Fig. 1A minus 1.

Further, the present invention includes polynucleotides comprising fragments specified by size, in nucleotides, rather than by nucleotide positions. The present invention includes any fragment size, in contiguous nucleotides, selected from integers between 1 and the entire length of an entire nucleotide sequence minus 1. Preferred sizes include 20 to 50 nucleotides; sizes of 50 to 300 nucleotides are useful as primers and probes. Regions from which typical sequences may be derived include, but are not limited to, for example,

regions encoding specific epitopes or domains within said sequence, such as domains C1-C5 shown in Fig. 1A.

In another aspect, the invention provides isolated nucleic acid molecules comprising polynucleotides which hybridize under stringent hybridization conditions to a polynucleotide sequence 30 of the present invention described above, for instance, a nucleic acid sequence shown in Fig. 1A or a specified fragment thereof. By "stringent hybridization conditions" is intended overnight incubation at 42°C in a solution comprising: 50% 35 formamide, 5X SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 g/ml denatured sheared salmon sperm DNA, followed by washing the filters in 0.1X SSC at about 65°C.

The sequences encoding the polypeptides of the present invention or portions thereof may be fused to other sequences which provide additional functions known in the art such as a marker sequence, or a sequence encoding a peptide which facilitates purification of the fused polypeptide, peptides having antigenic determinants known to provide helper T-cell stimulation, peptides encoding sites for post-translational modifications, or amino acid sequences in which target the fusion protein to a desired location, e.g., a heterologous leader sequence.

The present invention further relates to variants of the nucleic acid molecules of the present invention, which encode portions, analogs or derivatives of the sphingosine kinase type 2 isoform polypeptides shown in Fig. 1A. Variants may occur naturally, such as a natural allelic variant. By an "allelic variant" is intended one of several alternate forms of a gene occupying a given locus of a chromosome of an organism. Non-naturally occurring variants may be produced by known mutagenesis techniques. Such variants include those produced by nucleotide substitution, deletion or addition of one or more nucleotides in the coding or noncoding regions or both.

Alterations in the coding regions may produce conservative or nonconservative amino acid substitutions, deletions, or additions. Especially preferred among these are silent substitutions, additions, and deletions which do not alter the properties and activities of sphingosine kinase type 2 isoform polypeptides disclosed herein or portions thereof. Also preferred in this regard are conservative substitutions.

Nucleic acid molecules with at least 90-99% identity to a nucleic acid molecule which encodes a sphingosine kinase type 2 isoform shown in Fig. 1A is another aspect of the present invention. These nucleic acids are included irrespective of whether they encode a polypeptide having sphingosine kinase activity. By "a polypeptide having sphingosine kinase type 2 activity" is intended polypeptides exhibiting activity similar, but not identical, to an activity of the sphingosine kinase type 2 isoform of the present invention, as measured in the assays described below. The biological activity or function of the polypeptides of the present invention are expected to be similar or identical to, polypeptides from other organisms that share a high degree of structural identity/similarity.

In another embodiment, the present invention relates to a recombinant DNA molecule that includes a vector and a DNA sequence as described above. The vector can take the form of a plasmid, phage, cosmid, YAC, an eukaryotic expression vector such as a DNA vector, *Pichia pastoris*, or a virus vector such as for example, baculovirus vectors, retroviral vectors or adenoviral vectors, and others known in the art. The cloned gene may optionally be placed under the control of (i.e., operably linked to) certain control sequences such as promoter sequences, or sequences which may be inducible and/or cell type-specific. Suitable promoters are known to a person with ordinary skill in the art. The expression construct will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. Among the vectors preferred for use include

pCMV-SPORT2 (Life Technologies, Inc.), pCDNA3 (Invitrogen), to name a few.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, electroporation, infection, and other methods known in the art and described in standard laboratory manuals such as Current Protocols in Molecular Biology, Ausubel, F. M. et al. (Eds), Wiley & Sons, Inc. All documents cited herein supra and infra are hereby incorporated in their entirety by reference thereto.

In a further embodiment, the present invention relates to host cells stably transformed or transfected with the above-described recombinant DNA constructs. The host cell can be prokaryotic (for example, bacterial), lower eukaryotic (for example, yeast or insect) or higher eukaryotic (for example, all mammals, including, but not limited to, rat and human).

Both prokaryotic and eukaryotic host cells may be used for expression of desired coding sequences, when appropriate control sequences which are compatible with the designated host are used. Among prokaryotic hosts, *E. coli* is most frequently used. Expression control sequences for prokaryotes include promoters, optionally containing operator portions, and ribosome binding sites. Transfer vectors compatible with prokaryotic hosts are commonly derived from, for example, pBR322, a plasmid containing operons conferring ampicillin and tetracycline resistance, and the various pUC vectors, which also contain sequences conferring antibiotic resistance markers. These markers may be used to obtain successful transformants by selection. See, for example, Maniatis, Fritsch and Sambrook, Molecular Cloning: A Laboratory Manual, (1982) or DNA Cloning, Volumes I and II (D. N. Glover ed., 1985) for general cloning methods.

A transformant having a plasmid in which a cDNA encoding human SPHK2 is inserted, namely *E. coli* pCR3.1-hSPHK2 SANK 70200 has been deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science

and Technology, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken 305-8566, Japan, accession number FERM BP-7110, deposited March 29, 2000.

The DNA sequence can be present if the vector operably linked to a sequence encoding an IgG molecule, an adjuvant, a carrier, or an agent for aid in purification of SPHK, such as glutathione S-transferase, or a series of histidine residues also known as a histidine tag. The recombinant molecule can be suitable for transfecting eukaryotic cells, for example, mammalian cells and yeast cells in culture systems.

Saccharomyces cerevisiae, *Saccharomyces carlsbergensis*, and *Pichia pastoris* are the most commonly used yeast hosts, and are convenient fungal hosts. Control sequences for yeast vectors are known in the art. Mammalian cell lines are available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), such as HEK293 cells, and NIH 3T3 cells, to name a few. Suitable promoters are also known in the art and include viral promoters such as that from SV40, Rous sarcoma virus ("RSV"), adenovirus ("ADV"), bovine papilloma virus ("BPV"), and cytomegalovirus ("CMV").

Mammalian cells may also require terminator sequences and poly A addition sequences; enhancer sequences which increase expression may also be included, and sequences which cause amplification of the gene may also be desirable. These sequences are known in the art.

The transformed or transfected host cells can be used as a source of DNA sequences described above. When the recombinant molecule takes the form of an expression system, the transformed or transfected cells can be used as a source of the protein described below.

In another embodiment, the present invention relates to the employment of nucleotide sequences corresponding to GenBank/EMBL Data Bank accession nos. bankit325787 and bankit325752.

A polypeptide or amino acid sequence expressed from the nucleotide sequences discussed above, refers to polypeptide having an amino acid sequence identical to that of a polypeptide encoded from the sequence, or a portion thereof wherein the portion contains at least 2 to 5 amino acids, and more preferably at least 8 to 10 amino acids, and even more preferably at least 15 amino acids, or which is immunologically identifiable with a polypeptide encoded in the sequence.

A recombinant or derived polypeptide is not necessarily translated from a designated nucleic acid sequence; it may be generated in any manner, including, for example, chemical synthesis, or expression of a recombinant expression system. In addition the polypeptide can be fused to other proteins or polypeptides which increase its antigenicity, such as adjuvants, for example.

As noted above, the methods of the present invention are suitable for production of any polypeptide of any length, via insertion of the above-described nucleic acid molecules or vectors into a host cell and expression of the nucleotide sequence encoding the polypeptide of interest by the host cell. Introduction of the nucleic acid molecules or vectors into a host cell to produce a transformed host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as in Davis et al., Basic Methods In Molecular Biology, (1986).

Once transformed host cells have been obtained, the cells may be cultivated under any physiologically compatible conditions of pH and temperature, in any suitable nutrient medium containing assimilable sources of carbon, nitrogen and essential minerals that support host cell growth. Recombinant polypeptide-producing cultivation conditions vary according to the type of vector used to transform the host cells. For

example, certain expression vectors comprise regulatory regions which require cell growth at certain temperatures, or addition of certain chemicals or inducing agents to the cell growth medium, to initiate the gene expression resulting in the production of the recombinant polypeptide. Thus, the term "recombinant polypeptide-producing conditions," as used herein, is not meant to be limited to any one set of cultivation conditions. Appropriate culture media and conditions for the above-described host cells and vectors are well-known in the art. Following its production in the host cells, the polypeptide of interest may be isolated by several techniques. To liberate the polypeptide of interest from the host cells, the cells are lysed or ruptured. This lysis may be accomplished by contacting the cells with a hypotonic solution, by treatment with a cell wall-disrupting enzyme such as lysozyme, by sonication, by treatment with high pressure, or by a combination of the above methods. Other methods of bacterial cell disruption and lysis that are known to one of ordinary skill may also be used.

Following disruption, the polypeptide may be separated from the cellular debris by any technique suitable for separation of particles in complex mixtures. The polypeptide may then be purified by well-known isolation techniques. Suitable techniques for purification include, but are not limited to, ammonium sulfate or ethanol precipitation, acid extraction, electrophoresis, immunoabsorption, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, immunoaffinity chromatography, size exclusion chromatography, liquid chromatography (LC), high performance LC (HPLC), fast performance LC (FPLC), hydroxylapatite chromatography and lectin chromatography.

The recombinant or fusion protein can be used as a diagnostic tool and in a method for producing sphingosine-1-phosphate, detectably labeled and unlabeled, and

in a method for measuring levels of SPP in samples as described below. In addition, the recombinant protein can be used as a therapeutic agent to reduce cell death and/or increase cell proliferation. The transformed host cells can be used to analyze the effectiveness of drugs and agents which inhibit SPHK2 function, such as host proteins or chemically derived agents or other proteins which may interact with the cell to down-regulate or alter the expression of SPHK2, or its cofactors.

In another embodiment, the present invention relates to monoclonal or polyclonal antibodies specific for the above-described recombinant proteins (or polypeptides). For instance, an antibody can be raised against a peptide described above, or against, a portion thereof of at least 10 amino acids, preferably 11 to 15 amino acids. Persons with ordinary skill in the art using standard methodology can raise monoclonal and polyclonal antibodies to the protein (or polypeptide) of the present invention, or a unique portion thereof. Material and methods for producing antibodies are well known in the art (see, for example, Goding in Monoclonal Antibodies: Principles and Practice, Chapter 4, 1986).

The level of expression of sphingosine kinase type 2 can be detected at several levels. Using standard methodology well known in the art, assays for the detection and quantitation of sphingosine kinase type 2 RNA can be designed and include northern hybridization assays, *in situ* hybridization assays, and PCR assays, among others. See, for example, Maniatis, Fitsch and Sambrook, Molecular Cloning, A Laboratory- Manual, (1982) or DNA Cloning, Volumes I and II (D. N. Glover ed. 1985), or Current Protocols in Molecular Biology, Ausubel, F. M. et al., (Eds), Wiley & Sons, Inc. for a general description of methods for nucleic acid hybridization.

Polynucleotide probes for the detection of sphingosine kinase type 2 RNA can be designed from the sequence available at accession numbers AF068748 and/or AF068749 for the mouse

sequence (Kohama, T., et al., J. Biol. Chem., 273:23722-23728). For example, RNA isolated from samples can be coated onto a surface such as a nitrocellulose membrane and prepared for northern hybridization. In the case of *in situ* hybridization of biopsy samples, for example, the tissue sample can be prepared for hybridization by standard methods known in the art and hybridized with polynucleotide sequences which specifically recognize sphingosine kinase type 2 RNA. The presence of a hybrid formed between the sample RNA and the polynucleotide can be detected by any method known in the art such as radiochemistry, or immunochemistry, to name a few.

One of skill in the art may find it desirable to prepare probes that are fairly long and/or encompass regions of the amino acid sequence which would have a high degree of redundancy in the corresponding nucleic acid sequences. In other cases, it may be desirable to use two sets of probes simultaneously, each to a different region of the gene. While the exact length of any probe employed is not critical, typical probe sequences are no greater than 500 nucleotides, even more typically they are no greater than 250 nucleotides; they may be no greater than 100 nucleotides, and also may be no greater than 75 nucleotides in length. Longer probe sequences may be necessary to encompass unique polynucleotide regions with differences sufficient to allow related target sequences to be distinguished. For this reason, probes are preferably from about 10 to about 100 nucleotides in length and more preferably from about 20 to about 50 nucleotides.

The DNA sequence of sphingosine kinase type 2 can be used to design primers for use in the detection of sphingosine kinase type 2 using the polymerase chain reaction (PCR) or reverse transcription PCR (RT-PCR). The primers can specifically bind to the sphingosine kinase type 2 cDNA produced by reverse transcription of sphingosine kinase type 2 RNA, for the purpose of detecting the presence, absence, or quantifying the amount of sphingosine kinase type 2 by

comparison to a standard. The primers can be any length ranging from 7 to 40 nucleotides, preferably 10 to 35 nucleotides, most preferably 18 to 25 nucleotides homologous or complementary to a region of the sphingosine kinase type 2 sequence.

Reagents and controls necessary for PCR or RT-PCR reactions are well-known in the art. The amplified products can then be analyzed for the presence or absence of sphingosine kinase type 2 sequences, for example, by gel fractionation, by radiochemistry, and immunochemical techniques. This method is advantageous, since it requires a small number of cells. Once sphingosine kinase type 2 is detected, a determination of whether the cell is overexpressing or underexpressing sphingosine kinase type 2 can be made by comparison to the results obtained from a normal cell using the same method. Increased sphingosine kinase type 2 RNA levels correlate with increased cell proliferation and reduced cell death.

In another embodiment, the present invention relates to a diagnostic kit for the detection of sphingosine kinase type 2 RNA in cells. The kit comprises a package unit having one or more containers of sphingosine kinase type 2 oligonucleotide primers for detection of sphingosine kinase type 2 by PCR or RT-PCR or sphingosine kinase type 2 polynucleotides for the detection of sphingosine kinase type 2 RNA in cells by *in situ* hybridization or Northern analysis, and in some kits including containers of various reagents used for the method desired. The kit may also contain one or more of the following items: polymerization enzymes, buffers, instructions, controls, detection labels. Kits may include containers of reagents mixed together in suitable proportions for performing the methods in accordance with the invention. Reagent containers preferably contain reagents in unit quantities that obviate measuring steps when performing the subject methods.

In a further embodiment, the present invention provides a method for identifying and quantifying the level of sphingosine

kinase type 2 present in a particular biological sample. Any of a variety of methods which are capable of identifying (or quantifying) the level of sphingosine kinase type 2 in a sample can be used for this purpose.

Diagnostic assays to detect sphingosine kinase type 2 may comprise biopsy or *in situ* assay of cells from an organ or tissue sections, as well as an aspirate of cells from a tumor or normal tissue. In addition, assays may be conducted upon cellular extracts from organs, tissues, cells, urine, or serum or blood or any other body fluid or extract.

When assaying a biopsy, the assay will comprise contacting the sample to be assayed with a sphingosine kinase type 2 ligand, natural or synthetic, or an antibody, polyclonal or monoclonal, which recognizes sphingosine kinase type 2, or an antiserum capable of detecting sphingosine kinase type 2, and detecting the complex formed between sphingosine kinase type 2 present in the sample and the sphingosine kinase type 2 ligand or antibody added.

Sphingosine kinase type 2 ligands or substrates include for example, sphingosine, in addition to natural and synthetic classes of ligands and their derivatives which can be derived from natural sources such as animal or plant extracts. Other sphingosine kinase type 2 ligands include calmodulin.

Sphingosine kinase type 2 ligands or anti-sphingosine kinase type 2 antibodies, or fragments of ligand and antibodies capable of detecting sphingosine kinase type 2 may be labeled using any of a variety of labels and methods of labeling for use in diagnosis and prognosis of disease associated with increased cell proliferation, such as cancer, or reduced cell death. Examples of types of labels which can be used in the present invention include, but are not limited to enzyme labels, radioisotopic labels, nonradioactive isotopic labels, and chemiluminescent labels.

Examples of suitable enzyme labels include malate dehydrogenase, staphylococcal nuclease, delta-5-steroid

isomerase, yeast-alcohol dehydrogenase, alpha-glycerol phosphate dehydrogenase, triose phosphate isomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate hydrogenase, glucoamylase, acetylcholine esterase, etc.

Examples of suitable radioisotopic labels include ^3H , ^{111}In , ^{125}I , ^{32}P , ^{35}S , ^{14}C , ^{57}To , ^{58}Co , ^{59}Fe , ^{75}Se , ^{152}Eu , ^{90}Y , ^{67}Cu , ^{21}Ci , ^{211}At , ^{212}Pb , ^{47}Sc , ^{109}Pd , ^{11}C , ^{19}F and ^{131}I .

Examples of suitable non-radioactive isotopic labels include ^{157}Gd , ^{55}Mn , ^{162}Dy , ^{52}Tr and ^{46}Fe .

Examples of suitable fluorescent labels include a ^{152}Eu label, a fluorescein label, an isothiocyanate I label, a rhodamine label, a phycoerythrin label, a phycocyanin label, an allophycocyanin label and a fluorescamine label.

Examples of chemiluminescent labels include a luminal label, an isoluminal label, an aromatic acridinium ester label, an imidazole label, an acridinium salt label, an oxalate ester label, a luciferin label and a luciferase label.

Those of ordinary skill in the art will know of other suitable labels which may be employed in accordance with the present invention. The binding of these labels to ligands and to antibodies or fragments thereof can be accomplished using standard techniques commonly known to those of ordinary skill in the art. Typical techniques are described by Kennedy, J. H., et al., (1976), Clin. Chem. Acta., 70, 1-31, and Schurs, A. H. W. M., et al., (1977), Clin. Chem. Acta., 81, 1-40. Coupling techniques mentioned in the latter are the glutaraldehyde method, the periodate method, the daleamide method, and others.

The detection of the antibodies (or fragments of antibodies) of the present invention can be improved by the use of carriers. Well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses, and

magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration, so long as the coupled molecule is capable of binding to sphingosine kinase type 2. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet or test strip. Those of ordinary skill in the art will know many other suitable carriers for binding monoclonal antibody, or will be able to ascertain the same by the use of routine experimentation.

The ligands or antibodies, or fragments of antibodies or ligands of sphingosine kinase type 2 discussed above may be used to quantitatively or qualitatively detect the presence of sphingosine kinase type 2. Such detection may be accomplished using any of a variety of immunoassays known to persons of ordinary skill in the art such as radioimmunoassays, immunometric assays, etc. Using standard methodology well known in the art, a diagnostic assay can be constructed by coating on a surface (i.e., a solid support) for example, a microtitration plate or a membrane (e.g., a nitrocellulose membrane), antibodies specific for sphingosine kinase type 2 or a portion of sphingosine kinase type 2, and contacting it with a sample from a person suspected of having a sphingosine kinase type 2 related disease. The presence of a resulting complex formed between sphingosine kinase type 2 in the sample and antibodies specific therefor can be detected by any of the known detection methods common in the art, such as fluorescent antibody spectroscopy or colorimetry. A good description of a radioimmune assay may be found in Laboratory Techniques and Biochemistry in Molecular Biology by Work, T.S., et al., North Holland Publishing Company, N.Y. (1978), incorporated by reference herein. Sandwich assays are described by Wide at pages 199-206 of Radioimmune Assay Method, edited by Kirkham

and Hunter, E. & S. Livingstone, Edinburgh, 1970.

The diagnostic methods of this invention are predictive of proliferation and metastatic potentials in patients suffering from cancers including carcinomas of the lung, such as small cell carcinoma, large cell carcinoma, squamous carcinoma, and adenocarcinoma, stomach carcinoma, prostatic adenocarcinoma, ovarian carcinoma such as serous cystadenocarcinoma and mucinous cystadenocarcinoma, ovarian germ cell tumors, testicular carcinomas, and germ cell tumors, pancreatic adenocarcinoma, biliary adenocarcinoma, hepatocellular carcinoma, renal cell adenocarcinoma, endometrial carcinoma including adenocarcinomas and mixed Mullerian tumors (carcinosarcomas), carcinomas of the endocervix, ectocervix, and vagina such as adenocarcinoma and squamous carcinoma, basal cell carcinoma, melanoma, and skin appendage tumors, esophageal carcinoma, carcinomas of the nasopharynx and oropharynx including squamous carcinoma and adenocarcinomas, salivary gland carcinomas, brain and central nervous system tumors, including tumors of glial, neuronal, and meningeal origin, tumors of peripheral nerve, soft tissue sarcomas and sarcomas of bone and cartilage. Cells of these tumors which express increased levels of sphingosine kinase type 2, RNA or sphingosine kinase type 2 protein, have increased proliferation and decreased cell death.

The protein can be used to identify inhibitors of sphingosine kinase type 2 activity. Using an enzyme assay, natural and synthetic agents and drugs can be discovered which result in a reduction or elimination of sphingosine kinase type 2 enzymatic activity. Knowledge of the mechanism of action of the inhibitor is not necessary as long as a decrease in the activity of sphingosine kinase type 2 is detected. Inhibitors may include agents or drugs which either bind or sequester the enzyme's substrate(s) or cofactor(s), or inhibit the enzyme itself directly, for example, by irreversible binding of the agent or drug to the enzyme or indirectly, for example, by

introducing an agent which binds the sphingosine kinase type 2 substrate. Agents or drugs related to the present invention may result in partial or complete inhibition of sphingosine kinase type 2 activity.

Inhibitors of sphingosine kinase type 2 include DL-threo-dihydrosphingosine (DHS) and the more recently discovered inhibitor N,N-dimethylsphingosine ("DMS") described in Edsall, L. C. et al., (1998), Biochemistry, 37, 12892-12898. Inhibitors of sphingosine kinase type 2 may be used in the treatment or amelioration of diseases such as cancer, atherosclerosis, neurodegenerative disorders, i.e., stroke and Alzheimer's disease.

Agents which decrease the level of sphingosine kinase type 2 (i.e., in a human or an animal) or reduce or inhibit sphingosine kinase type 2 activity may be used in the therapy of any disease associated with the elevated levels of sphingosine kinase type 2 or diseases associated with increased cell proliferation, such as cancer. An increase in the level of sphingosine kinase type 2 is determined when the level of sphingosine kinase type 2 in a tumor cell is about 2 to 3 times the level of sphingosine kinase type 2 in the normal cell, up to about 10 to 100 times the amount of sphingosine kinase type 2 in a normal cell. Agents which decrease sphingosine kinase type 2 RNA include, but are not limited to, one or more ribozymes capable of digesting sphingosine kinase type 2 RNA, or antisense oligonucleotides capable of hybridizing to sphingosine kinase type 2 RNA, such that the translation of sphingosine kinase type 2 is inhibited or reduced resulting in a decrease in the level of sphingosine kinase type 2. These antisense oligonucleotides can be administered as DNA, as DNA entrapped in proteoliposomes containing viral envelope receptor proteins (Kanoda, Y. et al., (1989), Science, 5, 243, 375) or as part of a vector which can be expressed in the target cell such that the antisense DNA or RNA is made. Vectors which are expressed in particular cell types are known in the art, for

example, for the mammary gland. See Furth, J. Mammary Gland Biol. Neopl., 2, (1997), 373, for examples of conditional control of gene expression in the mammary gland.

Alternatively, the DNA can be injected along with a carrier. A carrier can be a protein such as a cytokine, for example, interleukin or a polylysine-glycoprotein carrier. Such carrier proteins and vectors and methods of using same are known in the art. In addition, the DNA could be coated onto tiny gold beads and such beads can be introduced into the skin with, for example, a gene gun (Ulmer, T. B. et al., Science, 259, (1993), 1745).

Alternatively, antibodies, or compounds capable of reducing or inhibiting sphingosine kinase type 2, that is reducing or inhibiting either the expression, production or activity of sphingosine kinase type 2, such as antagonists, can be provided as an isolated and substantially purified protein, or as part of an expression vector capable of being expressed in the target cell, such that the sphingosine kinase type 2 reducing or inhibiting agent is produced. In addition, co-factors such as various ions, i.e., Ca^{2+} or factors which affect the stability of the enzyme can be administered to modulate the expression and function of sphingosine kinase type 2. These formulations can be administered by standard routes. In general, the combinations may be administered by the topical, transdermal, intraperitoneal, oral, rectal, or parenteral (e.g., intravenous, subcutaneous, or intramuscular) route. In addition, sphingosine kinase type 2 inhibiting compounds may be incorporated into biodegradable polymers being implanted in the vicinity of where drug delivery is desired, for example, at the site of a tumor so that the sphingosine kinase type 2 inhibiting compound is slowly released systemically. The biodegradable polymers and their use are described, for example, in detail in Brem et al., J. Neurosurg., 74, (1991), 441-446. These compounds are intended to be provided to recipient subjects in an amount sufficient to

effect the inhibition of sphingosine kinase type 2. Similarly, agents which are capable of negatively affecting the expression, production, stability or function of sphingosine kinase type 2, are intended to be provided to recipient subjects in an amount sufficient to effect the inhibition of sphingosine kinase type 2. An amount is said to be sufficient to "effect" the inhibition or induction of sphingosine kinase type 2 if the dosage, route of administration, etc., of the agent are sufficient to influence such a response.

In line with the function of sphingosine kinase type 2 in cell proliferation, agents which stimulate the level of sphingosine kinase type 2, such as agonists of SPHK2, may be used in the therapy of any disease associated with a decrease of SPHK2, or a decrease in cell proliferation, wherein SPHK2 is capable of increasing such proliferation, e.g., developmental retardation.

In providing a patient with agents which modulate the expression or function of sphingosine kinase type 2 to a recipient patient, the dosage of administered agent will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition, previous medical history, etc. In general, it is desirable to provide the recipient with a dosage of agent which is in the range of from about 1 pg/kg to 10 mg/kg (body weight of patient), although a lower or higher dosage may be administered.

A composition is said to be "pharmacologically acceptable" if its administration can be tolerated by a recipient patient. Such an agent is said to be administered in a "therapeutically effective amount", if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient. The compounds of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby these materials, or their functional

derivatives, are combined in admixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in Remington's Pharmaceutical Sciences, 16th Ed., Osol, A. ed., Mack Easton PA. (1980). In order to form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the above-described compounds together with a suitable amount of carrier vehicle.

Additional pharmaceutical methods may be employed to control the duration of action. Control release preparations may be achieved through the use of polymers to complex or absorb the compounds. The controlled delivery may be exercised by selecting appropriate macromolecules (for example, polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the concentration of macromolecules as well as the method of incorporation in order to control release. Another possible method to control the duration of action by controlled release preparations is to incorporate the compounds of the present invention into particles of a polymeric material, such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, interfacial polymerization, for example, hydroxymethylcellulose for gelatin-microcapsules and poly(methylmethacrylate)microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (1980).

The present invention also provides kits for use in the diagnostic or therapeutic methods described above. Kits according to this aspect of the invention may comprise one or more containers, such as vials, tubes, ampules, bottles and the like, which may comprise one or more of the compositions of the invention.

The kits of the present invention may comprise one or more compounds or compositions of the present invention, and one or more excipients, diluents or adjuvants.

Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included herewith for purposes of illustration only and are not intended to be limiting of the present invention.

The following Materials and Methods were used in the Examples described below.

EXAMPLES

Materials

SPP, sphingosine, and N,N-dimethylsphingosine were from Biomol Research Laboratory Inc. (Plymouth Meeting, PA). All other lipids were purchased from Avanti Polar Lipids (Birmingham, AL). [g-32P]ATP (3000 Ci/mmol) was purchased from Amersham (Arlington Heights, IL). Poly-L-lysine and collagen were obtained from Boehringer Mannheim (Indianapolis, IN). Restriction enzymes were obtained from New England Biolabs (Beverly, MA). Poly(A)+ RNA blots of multiple mouse adult tissues were purchased from Clontech (Palo Alto, CA). "Lipofectamine PLUS" and "Lipofectamine" were obtained from Life Technologies, Inc. (Gaithersburg, MD).

Example 1: cDNA Cloning of Murine Sphingosine Kinase Type 2 (mSPHK2)

BLAST searches of the EST database identified a mouse EST clone (GenBank accession number AA839233) which had significant

homology to conserved domains of mSPHK1a (Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R. and Spiegel, S., J. Biol. Chem., 273, (1998), 23721-23728), yet had substantial sequence differences. Using this EST, a second isoform of SPHK, denoted mSPHK2, was cloned by two different PCR approaches.

In the first approach, the method PCR cloning from a mouse cDNA library (Stratagene) was used. Approximately 1×10^6 phage were plated on twenty 150 mm plates, plaques were collected, and plasmids were isolated using standard procedures (Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Smith, J. A., Seidman, J. G., and Struhl, K., Current Protocols in Molecular Biology, Green Publishing Associates and Wiley-Interscience, New York (1987)). An initial PCR reaction was carried out with a sequence specific primer (M-3-1, 5'-CCTGGGTGCACCTGCGCCTGTATTGG (SEQ ID NO: 1)) and the M13 reverse primer. The longest PCR products were gel purified and used as the template for a second PCR which contained a sequence specific antisense primer (M-3-2, 5'-CCAGTCTTGGGGCAGTGGAGAGCC-3' (SEQ ID NO:2)) and the T3 primer. The final PCR products were subcloned using a "TOPO TA" cloning kit (Invitrogen) and then sequenced. Platinum high fidelity DNA polymerase (Life Technologies) was used for the PCR amplifications with the following cycling parameters: 30 cycles of 94°C for 30 seconds, 55°C for 45 seconds, and 70°C for 2 minutes with a final primer extension at 72°C for 5 minutes.

In a second approach, 5'RACE PCR was performed with the 5'RACE System for Rapid Amplification of cDNA ends according to the manufacturer's protocol (Life Technologies). Poly(A)+ RNA was isolated from Swiss 3T3 fibroblasts using a Quick Prep mRNA Purification kit (Pharmacia). The first strand cDNA was synthesized at 42°C for 50 minutes with 5 mg of Swiss 3T3 poly(A)+ RNA using a target antisense primer designed from the sequence of AA839233 (m-GSP1, 5'-AGGTAGAGGCTTCTGG (SEQ ID NO:3)) and SuperScript II reverse transcriptase (Life

Technologies). Two consecutive PCR reactions using this cDNA as a template and LA Taq polymerase (TaKaRa) were carried out as follows: first PCR, 94°C for 2 minutes followed by 30 cycles of 94°C for 1 minute, 55°C for 1 minute, 72°C for 2 minutes, and primer extension at 72°C for 5 minutes with 5'RACE Abridged Anchor Primer, 5'-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG (SEQ ID NO:4) and the target specific antisense primer m-GSP2, 5'-GCGATGGGTGAAAGCTGAGCTG (SEQ ID NO:5); for the second PCR, the same conditions were employed, except that the annealing temperature was 65°C, with Abridged Universal Amplification Primer (AUAP), 5'-GGCCACGCGTCGACTAGTAC (SEQ ID NO:6) and m-GSP3, 5'-AGTCTCCAGTCAGCTCTGGACC (SEQ ID NO:7). PCR products were cloned into pCR2.1 and sequenced. The PCR products were subcloned into pCR3.1 and pCDNA 3 expression vectors.

Example 2: cDNA Cloning of Human Sphingosine Kinase-2(hSPHK2).

Poly(A)⁺ RNA from HEK293 cells was used for a 5'RACE reaction. Target specific antisense primers (h-GSP1, 5'-CCCACTCACTCAGGCT (SEQ ID NO:8); h-GSP2, 5'-GAAGGACAGCCCAGCTTCAGAG (SEQ ID NO:9); and h-GSP3, 5'-ATTGACCAATAGAAGCAACC (SEQ ID NO:10)) were designed according to the sequence of a human EST clone (accession number AA295570). A first strand cDNA was synthesized with 5 µg of HEK293 mRNA and h-GSP1. This cDNA was used as a template in an initial PCR reaction using 5'RACE Abridged Anchor Primer and h-GSP2. Then, a nested PCR was carried out using the AUAP primer and h-GSP3. The resulting PCR products were cloned and sequenced as described above.

Example 3: Overexpression and Activity of SPHK2

Human embryonic kidney cells (HEK293, ATCC CRL-1573) and NIH 3T3 fibroblasts (ATCC CRL-1658) were cultured as described in Olivera, A., Kohama, T., Edsall, L. C., Nava, V., Cuvillier, O., Poulton, S., and Spiegel, S., J. Cell Biol., **147**, (1999), 545-558. HEK293 cells were seeded at 6×10^5 per well in

poly-L-lysine coated 6 well plates. After 24 hours, cells were transfected with 1 µg of vector alone or with vectors containing sphingosine kinase constructs and 6 µl of "Lipofectamine PLUS" reagent plus 4 µl of "Lipofectamine" reagent per well. One to three days after transfection, cells were harvested and lysed by freeze-thawing as described in Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S., J. Biol. Chem., **273**, (1998), 23722-23728. In some experiments, cell lysates were fractionated into cytosol and membrane fractions by centrifugation at 100,000 x g for 60 minutes. SPHK activity was determined in the presence of sphingosine, prepared as a complex with 4 mg/ml BSA, and [γ-32P]ATP in kinase buffer (Olivera, A. and Spiegel, S. in Methods in Molecular Biology, (Bird, I.M. ed.), (1998), Vol. 105, 233-242, Humana Pres, Inc., Totowa, N.J.), containing 200 mM KCl, unless indicated otherwise. 32P-SPP was separated by TLC and quantified with a phosphoimager as previously described.

Example 4: Lipid Extraction and Measurement of SPP

Cells were washed with PBS and scraped in 1 ml of methanol containing 2.5 µl concentrated HCl. Lipids were extracted by adding 2 ml chloroform/1M NaCl (1:1, v/v) and 100 µl 3N NaOH and phases separated. The basic aqueous phase containing SPP, and devoid of sphingosine, ceramide, and the majority of phospholipids, was transferred to a siliconized glass tube. The organic phase was re-extracted with 1 ml methanol/1M NaCl (1:1, v/v) plus 50 µl 3N NaOH, and the aqueous fractions were combined. Mass measurement on SPP in the aqueous phase and total phospholipids in the organic phase were measured exactly as described in Edsall, L. C., Pirianov, G. G., and Spiegel, S., J. Neurosci., **17**, (1997) 6952-6960; Edsall, L. C., and Spiegel, S., Anal. Biochem., **272**, (1999) 80-86).

Example 5: Northern Blotting Analysis

Poly(A)+ RNA blots containing 2 µg of poly(A)+ RNA per lane from multiple adult mouse and human tissues and mouse embryos were purchased from Clontech. Blots were hybridized with the 1.2 kb PSTI fragment of mouse EST AA389187 (mSPHK1 probe), the 1.5 kb EcoRI fragment of pCR3.1-mSPHK2, or the 0.3 kb PvuII fragment of pCR3.1-hSPHK1, after gel-purification and labeling with [α-32P]dCTP. Hybridization in "ExpressHyb" buffer (Clontech) at 65°C overnight was carried out according to the manufacturer's protocol. Blots were reprobed with b-actin as a loading control (Clontech). Bands were quantified using a Molecular Dynamics Phosphoimager.

Results

Cloning of Type 2 Sphingosine Kinase

Blast searches of the EST data base identified several ESTs that displayed significant homology to the recently cloned mSPHK1a sequence. Specific primers were designed from the sequences of these ESTs and were used to clone a new type of mouse and human sphingosine kinase (named mSPHK2 and hSPHK2) by the approaches of PCR cloning from a mouse brain cDNA library and 5'-RACE PCR.

ClustalW alignment of the amino acid sequences of mSPHK2 and hSPHK2 is shown in Fig. 1A. The open reading frames of mSPHK2 and hSPHK2 encode polypeptides of 617 and 618 amino acids, respectively, with 83% identity and 90% similarity. Five highly conserved regions (C1 to C5), identified previously in SPHK1s (Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., Spiegel, S., *J. Biol. Chem.*, **273**, (1998) 23722-23728), are also present in both type 2 kinases. Interestingly, the invariant GGKGG positively charged motif in the C1 domain of SPHK1 is modified to GGRGL in SPHK2, suggesting that it may not be part of the ATP binding site as previously proposed (Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., Spiegel, S., *J. Biol. Chem.*, **273**,

(1998) 23722-23728). A motif search also revealed that a region beginning just before the conserved C1 domains of mSPHK2 and hSPHK2 (amino acid 147 to 284) also has homology to the diacylglycerol kinase catalytic site.

Compared to SPHK1, both SPHK2s encode much larger proteins containing 236 additional amino acids (Fig 1B). Moreover, their sequences diverge considerably from SPHK1 in the center and at the amino termini. However, after amino acid 140 of mSPHK2, the sequences of type 1 and type 2 SPHK have a large degree of similarity. These sequences (amino acid 9 to 226 for mSPHK1; 141 to 360 for mSPHK2), which encompass domains C1 to C4, have 47% identity and 79% similarity (Fig. 1B). In the C terminal portion of the proteins there are also large homologous regions, which include the C5 domain, from amino acid 227 to 381 for mSPHK1 and 480 to 617 for mSPHK2, with 43% identity and 78% similarity (Fig. 1B). The divergence in these domains suggests that SPHK2 probably did not arise as a simple gene duplication event.

Tissue Distribution of Sphingosine Kinase Type 2

The tissue distribution of SPHK2 mRNA expression in adult mouse was compared to that of SPHK1 by Northern blotting (Fig. 2A). In most tissues, including adult liver, heart, kidney, testis and brain, a predominant 3.1 kb SPHK2 mRNA species was detected, indicating ubiquitous expression. However, the level of expression was markedly variable and was highest in adult liver and heart and barely detectable in skeletal muscle and spleen (Fig. 2A). In contrast, the expression pattern of mSPHK1 was quite different, with the highest mRNA expression in adult lung, spleen, and liver, although expression in the liver did not predominate as with mSPHK2. mSPHK1 and mSPHK2 were both temporally and differentially expressed during embryonic development. mSPHK1 was expressed highly at mouse embryonic day 7 (E7) and decreased dramatically after E11 (Fig. 2B). In contrast, at

E7, mSPHK2 expression was much lower than mSPHK1, and gradually increased up to E17. The hSPHK2 2.8 kb mRNA transcript was mainly expressed in adult kidney, liver and brain, with much lower expression in other tissues (Fig. 2C). Interestingly, expression of SPHK2 in human kidney was very high and relatively much lower in the mouse, while the opposite pattern held for the liver.

Activity of Recombinant Sphingosine Kinase Type 2

To investigate whether mSPHK2 and hSPHK2 encode bona fide SPHKs, HEK293 cells were transiently transfected with expression vectors containing the corresponding cDNAs. Because previous studies have indicated that SPHK might be present in cells in both soluble and membrane-associated forms (Olivera, A., and Spiegel, S., Nature, **365**, (1993) 557-560; Banno, Y., Kato, M., Hara, A., and Nozawa, Y., Biochem. J., **335**, (1998) 301-304; Buehrer, B. M., and Bell, R. M., J. Biol. Chem., **267**, 3154-3159; Olivera, A., Rosenthal, J., and Spiegel, S., Anal. Biochem., **223**, (1994) 306-312; Ghosh, T. K., Bian, J., and Gill, D. L., J. Biol. Chem., **269**, (1994), 22628-22635), recombinant SPHK2 activity was measured both in cytosol and in membrane fractions of transfected cells. As previously described in Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S., J. Biol. Chem., **273**, (1998) 23722-23728, untreated or vector transfected HEK 293 cells have low levels of SPHK activity (Fig. 3A). Twenty four hours after transfection with mSPHK2 and hSPHK2, *in vitro* SPHK activity was increased by 20 and 35 fold, respectively, and then decreased thereafter (Fig.3A). In contrast, SPHK activity from cells transfected with mSPHK1 was much higher, 610-fold more than basal levels 24 hours after transfection and remaining at this level for at least 3 more days (data not shown). As in HEK293 cells, transfection of NIH 3T3 fibroblasts with mSPHK1 resulted in much higher SPHK activity than with mSPHK2. It was previously found that, similar to untransfected cells, the

majority of SPHK activity in cells transfected with mSPHK1 was cytosolic (Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S., J. Biol. Chem., **273**, (1998) 23722-23728). Similarly, in cells transfected with either mSPHK2 or hSPHK2, 17% and 26%, respectively, of the SPHK activity was membrane-associated (Fig. 3B), although Kyte-Doolittle hydropathy plots did not suggest the presence of hydrophobic membrane-spanning domains.

Transfection of HEK 293 cells with mSPHK2 and hSPHK2 also resulted in 2.2- and 3.3-fold increases in SPP, the product formed by SPHK, respectively (Fig. 3C), was in agreement with previous studies of sphingolipid metabolite levels after transfections with mSPHK1a showing a lack of correlation of fold increases in levels and in vitro enzyme activity (Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S., J. Biol. Chem., **273**, (1998) 23722-23728; Olivera, A., Kohama, T., Edsall, L. C., Nava, V., Cuvillier, O., Poulton, S., and Spiegel, S., J. Cell Biol., **147**, (1999), 545-558).

Characteristics of Recombinant mSPHK2

Substrate specificity

Although SPHK2 is highly homologous to SPHK1, there are substantial sequence differences. Therefore, it was of interest to compare their enzymatic properties. Typical Michaelis-Menten kinetics were observed for recombinant SPHK2 (data not shown). The K_m for D-erythro-sphingosine as substrate is 3.4 μM , almost identical to the K_m previously found for SPHK1 (Olivera, A., Kohama, T., Tu, Z., Milstien, S., and Spiegel, S., J. Biol. Chem., **273**, (1998), 12576-12583). Although the naturally occurring D-erythro-sphingosine isomer was the best substrate for SPHK1 (Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S., J. Biol. Chem., **273**, (1998) 23722-23728), D-erythro-dihydrosphingosine was a better substrate for SPHK2

than D-erythro-sphingosine (Fig. 4A). Moreover, although D,L-threo-dihydrosphingosine and phytosphingosine were not phosphorylated at all by SPHK1, they were significantly phosphorylated by SPHK2, albeit much less efficiently than sphingosine. Like SPHK1, other lipids including N,N-dimethylsphingosine (DMS), C2- or C16-ceramide, diacylglycerol, and phosphatidylinositol, were not phosphorylated by SPHK2 (Fig. 6A), suggesting high specificity for the sphingoid base.

DMS and DHS have previously been shown to be a potent competitive inhibitors of SPHK1 (Edsall, L. C., Van Brocklyn, J. R., Cuvillier, O., Kleuser, B., and Spiegel, S., Biochemistry, **37**, (1998), 12892-12898) and have been used to block increases in intracellular SPP levels resulting from various physiological stimuli (Olivera, A., and Spiegel, S., Nature, **365**, (1993), 557-560; Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coo, O. A., Gutkind, S., and Spiegel, S., Nature, **381**, (1996), 800-803; Edsall, L. C., Pirianov, G. G., and Spiegel, S., J. Neurosci, **17**, (1997), 6952-6960; Meyer zu Heringdorf, D., Lass, H., Alemany, R., Laser, K. T., Neumann, E., Zhang, C., Schmidt, M., Rauen, U., Jakobs, K. H., and van Koppen, C. J., EMBO J., **17**, 2830-2837; Choi, O. H., Kim, J.-H., and Kinet, J.-P., Nature, **380**, (1996), 634-636; Melendez, A., Floto, R. A., Gillooly, D. J., Harnett, M. M., and Allen, J. M., J. Biol. Chem., **273**, 9393-9402; Machwate, M., Rodan, S. B., Rodan, G. A., and Harada, S. I., Mol. Pharmacol., **54**, (1998), 70-77). However, because DHS is a substrate for SPHK2 and the product, dihydro SPP, is as potent as SPP in binding to and activating cell surface SPP EDG-1 family receptors, it cannot be used as a tool to investigate the role of SPHK2. Thus, it was important to characterize the inhibitory potential of the non-substrate DMS on SPHK2. Surprisingly, it was found that although DMS was also a potent inhibitor of SPHK2 (Fig. 4B), it acted in a non-competitive manner (Fig. 4C and Fig. 4D). The K_i for DMS with SPHK2 was 12

μM , slightly higher than the K_i of 4 μM with SPHK1, making it a useful tool to inhibit both types of SPHK.

mSPHK2 had highest activity in the neutral pH range from 6.5 to 8 with optimal activity at pH 7.5 (Fig. 5A), a pH dependency similar to that of SPHK1 (data not shown). The activity decreased markedly at pH values below and above this range.

Effects of KCl and NaCl

Most of the SPHK activity in human platelets is membrane-associated and extractable with 1 M NaCl (Banno, Y., Kato, M., Hara, A. and Nozawa, Y., Biochem. J., 335, (1998), 301-304). Furthermore, the salt extractable SPHK from platelets has different properties than the cytosolic enzyme. It was thus of interest to determine the effect of high salt concentrations on recombinant SPHK1 and SPHK2. Interestingly, it was found that high ionic strength had completely opposite effects on their activities. SPHK1 was inhibited markedly inhibited by either NaCl and KCl with each causing 50% inhibition at a concentration of 200 mM (Fig. 5B). In contrast, SPHK2 activity was dramatically stimulated by increasing the salt concentration, with a maximal effect at a concentration of 400 mM, although KCl was much more effective than NaCl. However, above this concentration, SPHK2 activity decreased sharply although remaining elevated even at 1 M salt (Fig. 5C). Thus, the activities of SPHK1 and SPHK2 have completely opposite responses to changes in ionic strength. Kinetic analysis of mSPHK2 in the presence and absence of high concentrations of salt indicated that the K_m for sphingosine was unaltered but the V_{max} was increased (Fig. 5D and Fig. 5E). The physiological significance of these observations remains to be determined but it might be related to different subcellular localizations.

Substrate presentation

Because sphingolipids are highly lipophilic, in *in vitro* SPHK assays, sphingosine is usually presented in micellar form with Triton X-100 or as a complex with BSA (Olivera, A., Rosenthal, J., and Spiegel, S., J. Cell. Biochem., **60**, (1996), 529-537; Olivera, A., Barlow, K. D., and Spiegel, S., Methods Enzymol, **311**, (2000), 215-223). Furthermore, detergents such as Triton X-100 have been shown to stimulate the activity of SPHK in rat brain extracts (Buehrer, B. M., and Bell, R. M., J. Biol. Chem., **267**, (1992), 3154-3159) and the enzyme from rat kidney (Olivera, A., Kohama, T., Tu, Z., Milstien, and Spiegel, S., J. Biol. Chem., **273**, (1998), 12576-12583), and it was previously found that the stability of rat kidney SPHK was increased in the presence of certain detergents (Olivera, A., Kohama, T., Tu, Z., Milstien, and Spiegel, S., J. Biol. Chem., **273**, (1998), 12576-12583). However, when the effect of increasing concentrations of Triton X-100 on the activities of SPHK1 and SPHK2 were compared, some unexpected results were found. Concentrations of detergent below 0.005% had no effect, but at higher concentrations, SPHK2 activity was inhibited and SPHK1 activity was markedly increased (Fig. 6A). At a concentration of Triton X-100 of 0.5%, SPHK1 activity was increased by more than 4 fold while SPHK2 was almost completely inhibited.

Interestingly, increasing the BSA concentration from the usual SPHK assay conditions with sphingosine-BSA complex as a substrate, i.e. 0.2 mg/ml BSA, caused a concentration-dependent inhibition of SPHK2 activity without affecting SPHK1 activity (Fig. 6B). Therefore, when measuring SPHK activity in cell or tissue extracts, the method of substrate preparation, whether in mixed micelles or in BSA complexes, must be carefully optimized because the differential effects of Triton X-100 and BSA on activity could yield different results depending on the relative expression of the two types of SPHK.

Effects of phospholipids

Acidic phospholipids, particularly phosphatidylserine, and phosphatidic acid and phosphatidylinositol, and cardiolipin to a lesser extent, induce a dose-dependent increase in SPHK activity Swiss 3T3 fibroblast lysates, whereas neutral phospholipids had no effect (Olivera, A., Rosenthal, J., and Spiegel, S., J. Cell. Biochem., 60, (1996), 529-537). In agreement, recombinant SPHK1 and SPHK2 were stimulated by phosphatidylserine; the activity of both was maximally increased 4-fold at a concentration of 40 µg/ml (Fig. 6C) and inhibited by higher concentrations in a dose-dependent manner. These effects of phosphatidylserine appeared to be specific since other phospholipids, including phosphatidylcholine, had no effect on the enzyme activity. In contrast, the activities of the three major forms of SPHK in human platelets are not affected by phosphatidylserine (Banno, Y., Kato, M., Hara, A, and Nozawa, Y., Biochem. J., 335, (1998), 301-304).

The mechanism by which phosphatidylserine enhances the enzymatic activity of SPHK is not yet understood. One possibility is that phosphatidylserine possesses unique membrane-structuring properties which better present the substrate, sphingosine. A second possibility is that SPHK contains determinants that specifically recognize the structure of the serine headgroup and that these determinants may only become exposed upon interaction of SPHK with membranes. In this regard, the molecular basis for the remarkable specificity of protein kinase C for phosphatidylserine has been the subject of much debate. However, recent data reveal that lipid structure and not membrane structure is the major determinant in the regulation of protein kinase C by phosphatidylserine (Johnson, J. E., Zimmerman, M. L., Daleke, D. L., and Newton, A. C., Biochemistry, 37, (1998), 12020-12025).

The presence of multiple ESTs in the database with significant homologies to SPHK1 as well as the identification

of several genes in *S. cerevisiae* encoding different SPHKs (Nagiec, M. M., Skrzypek, M., Nagiec, E. E., Lester, R. L., and Dickson, R. C., J. Biol. Chem., 273, (1998), 19437-19442) suggests that there may be a large and important SPHK gene family. Although SPHK2 has a high degree of homology to SPHK1, especially in the previously identified conserved domains identified in type 1 SPHKs (Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S., J. Biol. Chem., 273, (1998), 23722-23728), it is much larger (65.2 and 65.6 kDa for SPHK1 and SPHK2, respectively versus 42.4 kDa for mSPHK1a) and contains an additional 236 amino acids. Furthermore, its differential tissue expression, temporal developmental expression, cellular localization, and kinetic properties in response to increasing ionic strength and detergents, are completely different from SPHK1, suggesting that it most likely has a different function and regulates levels of SPP in a different manner than SPHK1 which is known to play a prominent role in regulating cell growth and survival. Thus, type 2 SPHK is considered to be involved in regulation of some of the numerous biological responses attributed to SPP, such as angiogenesis and allergic responses.

Sequence for GenBank 1 EMBC Bank Accession No.
bankit325787

```
1 aattcggcac gagggaggac cgagtaaacc gaggcttcca gaaccaaaga gaagtcagcc
61 tgaggaaagg gctgggaccc ggagcctctc tggcctttcc cgtccctgc tctaactctc
121 tccaggggta aagggaccgg agaatcagag acatgatcgg agcttgctgg acgagtcgcg
181 tggtgactct ctggccgcac gccgaccgct tctcgggtggc tcgcgaggga cccggtgggc
241 tgtgtgtcgg agcctccgaa gtagctggaa tcacgtctt tcaacacttg gcctggctct
301 gccatttaaa gttgtgatct tggaggctgg tccaggagct gaccacaagc caagagccta
361 ggagtgcctt ggactgaacc agggtcacatg cccaccacc actactgccg gtggctgccg
421 gcactccaat cctgcacggc gagtttggtt cctaccgggc caacggccca cggtttgccc
481 tcaccctcac aacacaagcc ctacacatac agcgactacg cccaaagcca gaagcccggc
541 cccgagatgg tctagtctct ctggatgagg tctcgggctg tggcaccctg cagagccgta
601 gccccgagga cactgcagcc tacttctgca tctacaccta cccacgtggc cgtcgagggg
661 gccggcgag agctacgcgg accttccggg cggatggggc caccacttat gaggagaatc
721 gtgcagaggc ccagcgctgg gccactgccc tcacgtgtct cctccgagga gtgcctctgt
781 caggggacca ggaaatcacc cctgaattgc tgccccggaa gccaggctg ctcatattgg
841 tcaatccctt tggggggcgg ggcttgccct ggcagcgctg tatggaccac gtggtgccaa
901 tgatctctga agctgggctg tccttcaacc tcatacagac agaacgacag aaccatgccc
961 gtgagctggg gcaggggtta agcctgagtg agtgggaagg cattgtcact gtgtctggag
1021 acgggctgct ttacgaggtg ctgaatgggc tccttgatcg gccagactgg gaggatgccg
1081 tgcggatgcc cattgggtgtc ctcccctgtg gatcgggcaa tgcgctagct ggggcggtga
1141 gccatcatgg cgggtttgag caggttgtcg gtgttgacct gttgctcaac tgctcgcttc
1201 ttctctgccg tgggtggcagc catcctctgg acttgcctct tgtgacgcta gcctcgggat
1261 cccgctgttt ttcttccctg tcagtggcct ggggattctt gtcagatgtg gacattcaca
1321 gtgagcgctt cagggccctg ggcagcgctc gattcacact ggggtgcagt ctaggcctgg
1381 cctcgttgca tacctaccgt ggacgcctct cctacctccc cgctaccaca gaaccagcct
1441 tgcccatccc aggccacagt ctgcctcgag ccaagtcaga actagtcttg gctccagccc
1501 cagcccccg cgcacccac tcgcctctac atcgatctgt gtctgacctg cccctgcccc
1561 ttccccagcc tgccctggtc tcccctggct cccctgagcc cctgcctgac ctgtccctca
1621 atgggtggtg tccagagctg actggagact ggggaggagc tggggatgca cctctgtccc
1681 cagaccact gctgccttca tccccaacg ctctcaaac agctcagctt tcaccatcg
1741 ctgaagggcc cccagaaatg ccagcatctt cggggttcct gcctcccacc cacagtgcct
1801 cagaagcctc tacctggggc ccagtggacc acctcctccc tcccctgggc tctccactgc
1861 cccaagactg ggtgacaata gagggggagt ttgtactcat gttgggcata ttgacgagcc
1921 acctctgcgc agacctgatg gcagccccac atgcacgctt tgatgatggc gttgtgcacc
1981 tgtgttgggt gcggagcggc atctcacggg ctgcacttct acgcattttt ctggccatgg
2041 agcatggaaa ccacttcagc ctgggctgcc cccatctggg ctatgctgca gcacgtgcct
```

2101 tccgccttga accactcacg cctcgtggcc tgctcactgt agatggggag ttagtggagt
 2161 atggggccaat acaggcgag gtgcaccag gtctcgccac gctgctcact gggcctgcag
 2221 gtcaaaagcc acaagcctga acgagcctaa aagcatggcg agttgggtga accagcgccc
 2281 cataggctaa gatctatcat ttacaggtag aagtggggcc cgcactcaga actgtgagga
 2341 ggggtggagag tggtcctgac cctcagttcc cagaggacct agaggctcga ggggtggggcc
 2401 tgcttttctt gatgtccaat gatggggcct ggaatgtatg agctagcaag gcttcttcag
 2461 cttattgacc agccagggtt tcttcttgcc tactccggtg cctctacttg actggccaat
 2521 cagcccttga ggggcagggt ccccgagtg gtccccagat ttgcactaat gtctctcccc
 2581 tggccagtta gggatgggat gttctgtgtc ttgtgtgtcc ctctccctag tctaaaaagc
 2641 aattgaaaag gtctatgcaa taaagggtgt tgcttccttc taaaaaaaaa aaaaaaaa

Sequence for Gen Bank 1 EMBC Bank Accession No.bankit325752

1 gccaccatgg ccccgcccc accgccactg gctgccagca ccccgctcct ccatggcgag
 61 tttggctcct acccagcccg agggccacgc tttgccctca cccttacatc gcaggccctg
 121 cacatacagc ggctgcgccc caaacctgaa gccaggcccc ggggtggcct ggtcccgttg
 181 gccgaggtct caggctgctg caccctgcga agccgcagcc cctcagactc agcggcctac
 241 ttctgcatct acacctacc tggggccgg cgccggggccc ggcgcagagc cactcgcccc
 301 ttccgggcag atggggccgc caccctacgaa gagaaccgtg ccgaggccca gcgctggggc
 361 actgccctca cctgtctgtc ccgaggactg cactgcccc gggatgggga gatccccct
 421 gacctgctac ctgcggccgc ccggttgctt ctattgggtc atccctttgg gggctggggc
 481 ctggcctggc agtgggtgaa gaaccacgtg ctcccatga tctctgaagc tgggtgtccc
 541 ttcaacctca tccagacaga acgacagaa caccgcccgg agctgggtcc ggggctgagc
 601 ctgagttagt gggatggcat cgtcacggtc tcggggagac ggctgtcca tgaggtgtg
 661 aacgggctcc tagatcgccc tgactgggag gaagctgtga agatgcctgt gggcatcctc
 721 ccctgcggct cgggcaacgc gctggccgga gcagtgaacc agcacggggg atttagacca
 781 gccctgggccc tcgacctgtt gctcaactgc tcaactgttg tgtgcccggg tgggtggccac
 841 cactggacc tgctctccgt gacgctggcc tcgggctccc gctgtttctc ctctctgtct
 901 gtggcctggg gcttcgtgtc agatgtggat atccagagcg agcgttccag ggccttgggc
 961 agtgcgcgct tcacactggg cacggtgctg ggcctcgcca cactgcacac ctaccgcgga
 1021 cgcctctcct acctccccgc cactgtggaa cctgcctcgc ccacctctgc ccatagcctg
 1081 cctcgtgcca agtcggagct gaccctaacc ccagaccag ccccgcccat ggccactca
 1141 cccctgcata gttctgtgtc tgacctgcct ctccacctgc ccagcctgc cctggcctct
 1201 cctggctcgc cagaacctct gccatcctg tcctcaacg gtgggggccc agagctggct
 1261 ggggactggg gtggggctgg ggatgctccg ctgtccccgg accactgct gtcttcacct
 1321 cctggctctc ccaaggcagc tctacactca cccgtctccg aaggggcccc cgtaattccc
 1381 ccatactctg ggctccact tcccacctct gatgcccggg taggggcctc cgacctgcggc
 1441 ccgcccagac acctgctgcc tccgctgggc acccgcctgc cccagactg gtgacgctg
 1501 gagggggact ttgtgctcat gttggccatc tcgcccagcc acctaggcgc tgacctggtg
 1561 gcagctccgc atgcgcgctt cgacgacggc ctgggtgcacc tgtgctgggt gcgtagcggc

1621 atctcgcggg ctgcgctgct ggccttttc ttggccatgg agcgtggtag ccacttcagc
 1681 ctgggctgtc cgcagctggg ctacgccg cgccgtgcct tccgcctaga gccgctcaca
 1741 ccacgcggcg tgctcacagt ggacggggag caggtggagt atgggccgct acaggcacag
 1801 atgcaccctg gcatcggtac actgctcact ggcctcctg gctgcccggg gggggagccc
 1861 tgaaactaaa caagcttggg acccgccggg gcggggcct acattccaat ggggcggagc
 1921 ttgagctagg ggggtgtggc tggctgctag agttgtggtg gcagggggcc tggccccgtc
 1981 tcaggattgc gctcgctttc atgggaccag acgtgatgct ggaagggtgg cgtcgtcacg
 2041 gttaaagaga aatgggctcg tcccagaggt agtcctgat caatgagggc ggggcctggc
 2101 gtctgatctg gggccgccct tacggggcag ggctcagtc tgacgcttgc cacctgctcc
 2161 taccgggcca ggatggctga gggcggagtc tattttacgc gtcgccaat gacaggacct
 2221 ggaatgtact ggctggggta ggcctcagtg agtcggccgg tcagggccc cagcctcgcc
 2281 ccatccactc cggtcctcc atttagctgg ccaatcagcc caggaggggc aggttccccg
 2341 gggccggcgc taggatttgc actaatgttc ctctccccgc

SEQ ID NO. 14

Amino acid sequences of human SPHK2

MAPPPPLAASTPLLHGEFGSYPARGPRFALTTLTSQALHIQRLRPKPEARPRGGLVPLAEVSGCCTLRSR
 SPDSAAAYFCIYTYPRGRRGARRRATRTFRADGAATYEENRAEAQRWATALTCLLRGLPLPGDGEITPDL
 LPRPPRLILLVNPFGGRGLAWQWCKNHVLP MISEAGLSFNLIQTERQNHARELVQGLSLSEWDGIVTVSG
 DGLLHEVLNGLLDRPDWEEAVKMPVGILPCGSGNALAGAVNQHGGEFEPALGLDLLLNCSLLLCRGGHPL
 DLLSVTLASGSRCSFSLVAVGFVSDVDIQSERFRALGSARFTLGTVLGLATLHTYRGRLSYLPATVEPA
 SPTPAHSLPRAKSELTLTPDPAPMAHSPHRSVSDLPPLPQPALASPGSPEPLPILSLNNGGGPELAGD
 WGGAGDAPLSPDPLLSSPPGSPKAAHSPVSEGAPVIPSSGLPLPTPDARVGASTCGPPDHLLPPLGTP
 LPDWDVTLEGDFVLM LAISPSHLGADLVAAPHARFDDGLVHLCWVRSGISRALLRLFLAMERGSFSLG
 CPHLG YAAARA FRLEPLTPRGVLTVDGEQVEYGPLQAQMHPIGIGTLLTGPPGCPGREP

SEQ ID NO. 12

Amino Acid Sequence of mouse SPHK2

MAPPPPLPVAASTPILHGEFGSYPANGPRFALTTLTQALHIQRLRPKPEARPRDGLVSLDEVSGCCTLQS
 RSPEDTAAAYFCIYTYPRGRRGGRRRATRTFRADGATTYEENRAEAQRWATALTCLLRGVPLSGDQEITPE
 LLPRKPRLILLVNPFGGRGLAWQRCMDHVVP MISEAGLSFNLIQTERQNHARELVQGLSLSEWEGIVTVS
 GDGLLYEVLNGLLDRPDWEDAVRMPIGVLP CGSGNALAGAVSHHGGEQVVGVDLLLNCSLLLCRGGSHP
 LDLLSVTLASGSRCSFSLVAVGFSLSDVDIHSEFRALGSARFTLGAVLGLASLHTYRGRLSYLPATTEP
 ALPIPGHSLPRAKSELVLAPAPAPAATHSPLHRSVSDLPPLPQPALVSPGSPEPLPDLNNGGGPELTG
 DWGGAGDAPLSPDPLLSPSPNALKTAQLSPIAEGPPEMPASSGFLPPTHSAPEASTWGPVDHLLPPLGSP
 LPQDWVTIEGEFVLM LGILTSHLCADLMAAPHARFDDGVVHLCWVRSGISRALLRIFLAMEHGNHFSLG
 CPHLG YAAARA FRLEPLTPRGLLTVDGELVEYGPIQAQVHPGLATLLTGPAQKPQA

SEQUENCE LISTING

<110> SANKYO COMPANY, LIMITED
GEORGETOWN UNIVERSITY

<120> Mammalian Sphingosine Kinase Type 2 Isoforms, Cloning,
Expression and Methods of Use Thereof

<130> 00170PCT/HG

<140>

<141>

<150> US 60/194,318

<151> 2000-04-03

<160> 15

<170> PatentIn Ver. 2.0

<210> 1

<211> 26

<212> DNA

<213> Mus musculus

<400> 1

cctgggtgca cctgcgcctg tattgg

26

<210> 2

<211> 24

<212> DNA

<213> Mus musculus

<400> 2

ccagtctttgg ggcagtggag agcc

24

<210> 3
<211> 18
<212> DNA
<213> Mus musculus

<400> 3
aggtagaggc ttctgg

18

<210> 4
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: 5' RAGE
Abridged Anchor Primer

<220>
<221> modified_base
<222> (24).. (25)
<223> i

<220>
<221> modified_base
<222> (29).. (30)
<223> i

<220>
<221> modified_base
<222> (34).. (35)
<223> i

<400> 4
ggccacgcgt cgactagtac gggnggggnn gggngg

36

<210> 5

<211> 22

<212> DNA

<213> Mus musculus

<400> 5

gcgatgggtg aaagctgagc tg

22

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Abridged
Universal Amplification Primer

<400> 6

ggccacgggt cgactagtac

20

<210> 7

<211> 22

<212> DNA

<213> Mus musculus

<400> 7

agtctccagt cagctctgga cc

22

<210> 8

<211> 16

<212> DNA

<213> Homo sapiens

<400> 8

cccactcact caggct

16

<210> 9

<211> 22

<212> DNA

<213> Homo sapiens

<400> 9

gaaggacagc ccagcttcag ag

22

<210> 10

<211> 20

<212> DNA

<213> Homo sapiens

<400> 10

attgaccaat agaagcaacc

20

<210> 11

<211> 2698

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (387).. (2237)

<300>

<302> Molecular cloning and functional characterization of a
novel mammalian sphingosine kinase type 2 isoform

<303> J. Biol. Chem.

<304> 275

<305> 26

<306> 19513-19520

<308> AF245448

<400> 11

aattcggcac gagggaggac cgagtaaacc gaggttcca gaaccaaaga gaagtcagcc 60
tgaggaaagg gctgggaccc ggagcctctc tggcctttcc cgtccctgc tctaacactc 120
tccaggggta aaggggacgg agaatacagag acatgatcgg agcttgctgg acgagtcgcz 180
tggtgactct ctggccgcac gccgacogct tctcggtggc tcgaggagga cccggtggc 240
tgtgtgtcgg agcctccgaa gtagctggaa tcaccgtctt tcaacacttg gectggctct 300
gccatttaaa gttgtgatct tggaggtcgg tccaggagct gaccacaagc caagagccta 360
ggagtgttg ggaactgaacc agggtc atg gcc cca cca cca cta ctg cca gtg 413
Met Ala Pro Pro Pro Leu Leu Pro Val
1 5
got gcc agc act cca atc ctg cac ggc gag ttt ggt tcc tac cgc gcc 461
Ala Ala Ser Thr Pro Ile Leu His Gly Glu Phe Gly Ser Tyr Pro Ala
10 15 20 25
aac ggc cca egg ttt gcc ctg acc ctg aca aca caa gcc cta cac ata 509
Asn Gly Pro Arg Phe Ala Leu Thr Leu Thr Thr Gln Ala Leu His Ile
30 35 40
cag cga cta cgc cca aag cca gaa gcc cgg ccc cga gat ggt cta gtc 557
Gln Arg Leu Arg Pro Lys Pro Glu Ala Arg Pro Arg Asp Gly Leu Val
45 50 55
tct ctg gat gag gtc tcg ggc tgt ggc acc ctg cag agc cgt agc ccc 605
Ser Leu Asp Glu Val Ser Gly Cys Gly Thr Leu Gln Ser Arg Ser Pro
60 65 70
gag gac act gca gcc tac ttc tgc atc tac acc tac cca cgt ggc cgt 653
Glu Asp Thr Ala Ala Tyr Phe Cys Ile Tyr Thr Tyr Pro Arg Gly Arg
75 80 85
cga ggg ggc cgg cgc aga gct acg cgg acc ttc cgg gcg gat ggg gcc 701
Arg Gly Gly Arg Arg Arg Ala Thr Arg Thr Phe Arg Ala Asp Gly Ala

90	95	100	105	
acc act tat gag gag aat cgt gca gag gcc cag cgc tgg gcc act gcc	749			
Thr Thr Tyr Glu Glu Asn Arg Ala Glu Ala Gln Arg Trp Ala Thr Ala				
110	115	120		
ctc acg tgt ctc ctc cga gga gtg cct ctg tca ggg gac cag gaa atc	797			
Leu Thr Cys Leu Leu Arg Gly Val Pro Leu Ser Gly Asp Gln Glu Ile				
125	130	135		
acc cct gaa ttg ctg ccc cgg aag ccc agg ctg ctc ata ttg gtc aat	845			
Thr Pro Glu Leu Leu Pro Arg Lys Pro Arg Leu Leu Ile Leu Val Asn				
140	145	150		
ccc ttt ggg ggg cgg ggc ctg gcc tgg cag cgc tgt atg gac cac gtg	893			
Pro Phe Gly Gly Arg Gly Leu Ala Trp Gln Arg Cys Met Asp His Val				
155	160	165		
gtg cca atg atc tct gaa gct ggg ctg tcc ttc aac ctc ata cag aca	941			
Val Pro Met Ile Ser Glu Ala Gly Leu Ser Phe Asn Leu Ile Gln Thr				
170	175	180	185	
gaa cga cag aac cat gcc cgt gag ctg gtg cag ggg tta agc ctg agt	989			
Glu Arg Gln Asn His Ala Arg Glu Leu Val Gln Gly Leu Ser Leu Ser				
190	195	200		
gag tgg gaa ggc att gtc act gtg tct gga gac ggg ctg ott tac gag	1037			
Glu Trp Glu Gly Ile Val Thr Val Ser Gly Asp Gly Leu Leu Tyr Glu				
205	210	215		
gtg ctg aat ggg ctc ott gat cgg cca gac tgg gag gat gcc gtg cgg	1085			
Val Leu Asn Gly Leu Leu Asp Arg Pro Asp Trp Glu Asp Ala Val Arg				
220	225	230		
atg ccc att ggt gtc ctc ccc tgt gga tgg ggc aat ggc cta gct ggg	1133			
Met Pro Ile Gly Val Leu Pro Cys Gly Ser Gly Asn Ala Leu Ala Gly				
235	240	245		

ggc gtg agc cat cat ggc ggg ttt gag cag gtt gtc ggt gtt gac ctg 1181
 Ala Val Ser His His Gly Gly Phe Glu Gln Val Val Gly Val Asp Leu
 250 255 260 265

ttg ctc aac tgc tgc ctt ctt ctc tgc cgt ggt ggc agc cat cct ctg 1229
 Leu Leu Asn Cys Ser Leu Leu Leu Cys Arg Gly Gly Ser His Pro Leu
 270 275 280

gac ttg ctc tct gtg acg cta gcc tgc gga tcc cgc tgt ttt tcc ttc 1277
 Asp Leu Leu Ser Val Thr Leu Ala Ser Gly Ser Arg Cys Phe Ser Phe
 285 290 295

ctg tca gtg gcc tgg gga ttc ttg tca gat gtg gac att cac agt gag 1325
 Leu Ser Val Ala Trp Gly Phe Leu Ser Asp Val Asp Ile His Ser Glu
 300 305 310

cgc ttc agg gcc ctg ggc agc gct cga ttc aca ctg ggt gca gtg cta 1373
 Arg Phe Arg Ala Leu Gly Ser Ala Arg Phe Thr Leu Gly Ala Val Leu
 315 320 325

ggc ctg gcc tgc ttg cat acc tac cgt gga cgc ctc tcc tac ctc ccc 1421
 Gly Leu Ala Ser Leu His Thr Tyr Arg Gly Arg Leu Ser Tyr Leu Pro
 330 335 340 345

gct acc aca gaa cca gcc ttg ccc atc cca ggc cac agt ctg cct cga 1469
 Ala Thr Thr Glu Pro Ala Leu Pro Ile Pro Gly His Ser Leu Pro Arg
 350 355 360

gcc aag tca gaa cta gtc ttg gct cca gcc cca gcc ccc gcc gcc acc 1517
 Ala Lys Ser Glu Leu Val Leu Ala Pro Ala Pro Ala Pro Ala Ala Thr
 365 370 375

cac tgc cct cta cat cga tct gtg tct gac ctg ccc ctg ccc ctt ccc 1565
 His Ser Pro Leu His Arg Ser Val Ser Asp Leu Pro Leu Pro Leu Pro
 380 385 390

cag cct gcc ttg gtc tcc cct ggc tcc cct gag ccc ctg cct gac ctg 1613
 Gln Pro Ala Leu Val Ser Pro Gly Ser Pro Glu Pro Leu Pro Asp Leu

395	400	405	
tcc etc aat ggt ggt ggt cca gag ctg act gga gac tgg gga gga got			1681
Ser Leu Asn Gly Gly Gly Pro Glu Leu Thr Gly Asp Trp Gly Gly Ala			
410	415	420	425
ggg gat gca cct ctg tcc cca gac cca ctg ctg cct tca tcc ccc aac			1709
Gly Asp Ala Pro Leu Ser Pro Asp Pro Leu Leu Pro Ser Ser Pro Asn			
	430	435	440
get etc aaa aca get cag ctt tca ccc atc get gaa ggg ccc cca gaa			1757
Ala Leu Lys Thr Ala Gln Leu Ser Pro Ile Ala Glu Gly Pro Pro Glu			
	445	450	455
atg cca gca tet tgg ggg ttc ctg cct ccc acc cac agt gcc cca gaa			1805
Met Pro Ala Ser Ser Gly Phe Leu Pro Pro Thr His Ser Ala Pro Glu			
	460	465	470
gcc tct acc tgg ggc cca gtg gac cac etc etc cct ccc ctg ggc tct			1853
Ala Ser Thr Trp Gly Pro Val Asp His Leu Leu Pro Pro Leu Gly Ser			
	475	480	485
cca ctg ccc caa gac tgg gtg aca ata gag ggg gag ttt gta etc atg			1901
Pro Leu Pro Gln Asp Trp Val Thr Ile Glu Gly Glu Phe Val Leu Met			
490	495	500	505
ttg ggc atc ttg acg agc cac etc tgc gca gac ctg atg gca gcc cca			1949
Leu Gly Ile Leu Thr Ser His Leu Cys Ala Asp Leu Met Ala Ala Pro			
	510	515	520
cat gca cgc ttt gat gat ggc gtt gtg cac ctg tgt tgg gtg cgg agc			1997
His Ala Arg Phe Asp Asp Gly Val Val His Leu Cys Trp Val Arg Ser			
	525	530	535
ggc atc tca cgg got gca ctt cta cgc att ttt ctg gcc atg gag cat			2045
Gly Ile Ser Arg Ala Ala Leu Leu Arg Ile Phe Leu Ala Met Glu His			
	540	545	550

gga aac cac ttc agc ctg ggc tgc ccc cat ctg ggc tat gct gca gca 2093
 Gly Asn His Phe Ser Leu Gly Cys Pro His Leu Gly Tyr Ala Ala Ala
 555 560 565

cgt gcc ttc cgc ott gaa cca ctc acg cct cgt ggc ctg ctc act gta 2141
 Arg Ala Phe Arg Leu Glu Pro Leu Thr Pro Arg Gly Leu Leu Thr Val
 570 575 580 585

gat ggg gag ttá gtg gag tat ggg cca ata cag gcg cag gtg cac cca 2189
 Asp Gly Glu Leu Val Glu Tyr Gly Pro Ile Gln Ala Gln Val His Pro
 590 595 600

ggt ctc gcc acg ctg ctc act ggg cct gca ggt caa aag cca caa gcc 2237
 Gly Leu Ala Thr Leu Leu Thr Gly Pro Ala Gly Gln Lys Pro Gln Ala
 605 610 615

tgaacgagcc taaaagcatg gcgagttggt ggaaccagcg ccccataggc taagatctat 2297

catttacagg tagaagtggg gcccgcactc agaactgtga ggagggtgga gagtggctcct 2357

gaccctcagt tcccagagga cctagagget cgagggtggg gcctgccttt ettgatgtcc 2417

aatgatgggg cctggaatgt atgagctagc aaggettctt cagcttattg accagccagg 2477

gtttctctctt gcctactccg gtgcctctac ttgactggcc aatcagccct tgaggggcag 2537

gttccccag gtggtcccca gatttgcact aatgttccct ccctggccag ttagggatgg 2597

gatgttctgt gtcttgtgtg tccctctccc tagtctaaaa agcaattgaa aaggtctatg 2657

caataaagggt tgttgcttcc ctctaaaaaa aaaaaaaaaa a 2698

<210> 12

<211> 617

<212> PRT

<213> Mus musculus

<400> 12

Met Ala Pro Pro Pro Leu Leu Pro Val Ala Ala Ser Thr Pro Ile Leu
 1 5 10 15

His Gly Glu Phe Gly Ser Tyr Pro Ala Asn Gly Pro Arg Phe Ala Leu
 20 25 30

Thr Leu Thr Thr Gln Ala Leu His Ile Gln Arg Leu Arg Pro Lys Pro
 35 40 45

Glu Ala Arg Pro Arg Asp Gly Leu Val Ser Leu Asp Glu Val Ser Gly
 50 55 60

Cys Gly Thr Leu Gln Ser Arg Ser Pro Glu Asp Thr Ala Ala Tyr Phe
 65 70 75 80

Cys Ile Tyr Thr Tyr Pro Arg Gly Arg Arg Gly Gly Arg Arg Arg Ala
 85 90 95

Thr Arg Thr Phe Arg Ala Asp Gly Ala Thr Thr Tyr Glu Glu Asn Arg
 100 105 110

Ala Glu Ala Gln Arg Trp Ala Thr Ala Leu Thr Cys Leu Leu Arg Gly
 115 120 125

Val Pro Leu Ser Gly Asp Gln Glu Ile Thr Pro Glu Leu Leu Pro Arg
 130 135 140

Lys Pro Arg Leu Leu Ile Leu Val Asn Pro Phe Gly Gly Arg Gly Leu
 145 150 155 160

Ala Trp Gln Arg Cys Met Asp His Val Val Pro Met Ile Ser Glu Ala
 165 170 175

Gly Leu Ser Phe Asn Leu Ile Gln Thr Glu Arg Gln Asn His Ala Arg
 180 185 190

Glu Leu Val Gln Gly Leu Ser Leu Ser Glu Trp Glu Gly Ile Val Thr

195	200	205
Val Ser Gly Asp Gly Leu Leu Tyr Glu Val Leu Asn Gly Leu Leu Asp		
210	215	220
Arg Pro Asp Trp Glu Asp Ala Val Arg Met Pro Ile Gly Val Leu Pro		
225	230	235 240
Cys Gly Ser Gly Asn Ala Leu Ala Gly Ala Val Ser His His Gly Gly		
245	250	255
Phe Glu Gln Val Val Gly Val Asp Leu Leu Leu Asn Cys Ser Leu Leu		
260	265	270
Leu Cys Arg Gly Gly Ser His Pro Leu Asp Leu Leu Ser Val Thr Leu		
275	280	285
Ala Ser Gly Ser Arg Cys Phe Ser Phe Leu Ser Val Ala Trp Gly Phe		
290	295	300
Leu Ser Asp Val Asp Ile His Ser Glu Arg Phe Arg Ala Leu Gly Ser		
305	310	315 320
Ala Arg Phe Thr Leu Gly Ala Val Leu Gly Leu Ala Ser Leu His Thr		
325	330	335
Tyr Arg Gly Arg Leu Ser Tyr Leu Pro Ala Thr Thr Glu Pro Ala Leu		
340	345	350
Pro Ile Pro Gly His Ser Leu Pro Arg Ala Lys Ser Glu Leu Val Leu		
355	360	365
Ala Pro Ala Pro Ala Pro Ala Ala Thr His Ser Pro Leu His Arg Ser		
370	375	380
Val Ser Asp Leu Pro Leu Pro Leu Pro Gln Pro Ala Leu Val Ser Pro		
385	390	395 400

Gly Ser Pro Glu Pro Leu Pro Asp Leu Ser Leu Asn Gly Gly Gly Pro
 405 410 415

Glu Leu Thr Gly Asp Trp Gly Gly Ala Gly Asp Ala Pro Leu Ser Pro
 420 425 430

Asp Pro Leu Leu Pro Ser Ser Pro Asn Ala Leu Lys Thr Ala Gln Leu
 435 440 445

Ser Pro Ile Ala Glu Gly Pro Pro Glu Met Pro Ala Ser Ser Gly Phe
 450 455 460

Leu Pro Pro Thr His Ser Ala Pro Glu Ala Ser Thr Trp Gly Pro Val
 465 470 475 480

Asp His Leu Leu Pro Pro Leu Gly Ser Pro Leu Pro Gln Asp Trp Val
 485 490 495

Thr Ile Glu Gly Glu Phe Val Leu Met Leu Gly Ile Leu Thr Ser His
 500 505 510

Leu Cys Ala Asp Leu Met Ala Ala Pro His Ala Arg Phe Asp Asp Gly
 515 520 525

Val Val His Leu Cys Trp Val Arg Ser Gly Ile Ser Arg Ala Ala Leu
 530 535 540

Leu Arg Ile Phe Leu Ala Met Glu His Gly Asn His Phe Ser Leu Gly
 545 550 555 560

Cys Pro His Leu Gly Tyr Ala Ala Ala Arg Ala Phe Arg Leu Glu Pro
 565 570 575

Leu Thr Pro Arg Gly Leu Leu Thr Val Asp Gly Glu Leu Val Glu Tyr
 580 585 590

Gly Pro Ile Gln Ala Gln Val His Pro Gly Leu Ala Thr Leu Leu Thr
 595 600 605

Gly Pro Ala Gly Gln Lys Pro Gln Ala
 610 615

<210> 13
 <211> 2380
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (7)..(1860)

<300>
 <302> Molecular cloning and functional characterization of a
 novel mammalian sphingosine kinase type 2 isoform
 <303> J. Biol. Chem.
 <304> 275
 <305> 28
 <306> 19513-19520
 <308> AF245447

<400> 13
 gccacc atg gcc ccg ccc cca ccg cca ctg gct gcc agc acc ccg etc 48
 Met Ala Pro Pro Pro Pro Pro Leu Ala Ala Ser Thr Pro Leu
 1 5 10
 etc cat ggc gag ttt ggc tcc tac cca gcc cga ggc cca cgc ttt gcc 96
 Leu His Gly Glu Phe Gly Ser Tyr Pro Ala Arg Gly Pro Arg Phe Ala
 15 20 25 30
 etc acc ctt aca tcg cag gcc ctg cac ata cag cgg ctg cgc ccc aaa 144
 Leu Thr Leu Thr Ser Gln Ala Leu His Ile Gln Arg Leu Arg Pro Lys
 35 40 45
 cct gaa gcc agg ccc cgg ggt gcc ctg gtc ccg ttg gcc gag gtc tca 192
 Pro Glu Ala Arg Pro Arg Gly Gly Leu Val Pro Leu Ala Glu Val Ser

50	55	60	
ggc tgc tgc acc ctg cga agc cgc agc ccc tca gac tca gcg gcc tac			240
Gly Cys Cys Thr Leu Arg Ser Arg Ser Pro Ser Asp Ser Ala Ala Tyr			
65	70	75	
ttc tgc atc tac acc tac cct cgg ggc cgg cgc ggg gcc cgg cgc aga			288
Phe Cys Ile Tyr Thr Tyr Pro Arg Gly Arg Arg Gly Ala Arg Arg Arg			
80	85	90	
gcc act cgc acc ttc cgg gca gat ggg gcc gcc acc tac gaa gag aac			336
Ala Thr Arg Thr Phe Arg Ala Asp Gly Ala Ala Thr Tyr Glu Glu Asn			
95	100	105	110
cgt gcc gag gcc cag cgc tgg gcc act gcc ctc acc tgt ctg ctc cga			384
Arg Ala Glu Ala Gln Arg Trp Ala Thr Ala Leu Thr Cys Leu Leu Arg			
115	120	125	
gga ctg cca ctg ccc ggg gat ggg gag atc acc cct gac ctg cta cct			432
Gly Leu Pro Leu Pro Gly Asp Gly Glu Ile Thr Pro Asp Leu Leu Pro			
130	135	140	
cgg cgg ccc cgg ttg ctt cta ttg gtc aat ccc ttt ggg ggt cgg gcc			480
Arg Pro Pro Arg Leu Leu Leu Leu Val Asn Pro Phe Gly Gly Arg Gly			
145	150	155	
ctg gcc tgg cag tgg tgt aag aac cac gtg ctt ccc atg atc tct gaa			528
Leu Ala Trp Gln Trp Cys Lys Asn His Val Leu Pro Met Ile Ser Glu			
160	165	170	
gct ggg ctg tcc ttc aac ctc atc cag aca gaa cga cag aac cac gcc			576
Ala Gly Leu Ser Phe Asn Leu Ile Gln Thr Glu Arg Gln Asn His Ala			
175	180	185	190
cgg gag ctg gtc cag ggg ctg agc ctg agt gag tgg gat gcc atc gtc			624
Arg Glu Leu Val Gln Gly Leu Ser Leu Ser Glu Trp Asp Gly Ile Val			
195	200	205	

acg gtc tgc gga gac ggg ctg ctc cat gag gtg ctg aac ggg ctc cta 672
 Thr Val Ser Gly Asp Gly Leu Leu His Glu Val Leu Asn Gly Leu Leu
 210 215 220

gat cgc cct gac tgg gag gaa gct gtg aag atg cct gtg ggc atc ctc 720
 Asp Arg Pro Asp Trp Glu Glu Ala Val Lys Met Pro Val Gly Ile Leu
 225 230 235

ccc tgc ggc tgc ggc aac ggc ctg gcc gga gca gtg aac cag cac ggg 768
 Pro Cys Gly Ser Gly Asn Ala Leu Ala Gly Ala Val Asn Gln His Gly
 240 245 250

gga ttt gag cca gcc ctg ggc ctc gac ctg ttg ctc aac tgc tca ctg 816
 Gly Phe Glu Pro Ala Leu Gly Leu Asp Leu Leu Leu Asn Cys Ser Leu
 255 260 265 270

ttg ctg tgc cgg ggt ggt ggc cac cca ctg gac ctg ctc tcc gtg acg 864
 Leu Leu Cys Arg Gly Gly Gly His Pro Leu Asp Leu Leu Ser Val Thr
 275 280 285

ctg gcc tgc ggc tcc cgc tgt ttc tcc ttc ctg tct gtg gcc tgg ggc 912
 Leu Ala Ser Gly Ser Arg Cys Phe Ser Phe Leu Ser Val Ala Trp Gly
 290 295 300

ttc gtg tca gat gtg gat atc cag agc gag cgc ttc agg gcc ttg ggc 960
 Phe Val Ser Asp Val Asp Ile Gln Ser Glu Arg Phe Arg Ala Leu Gly
 305 310 315

agt gcc cgc ttc aca ctg ggc acg gtg ctg ggc ctc gcc aca ctg cac 1008
 Ser Ala Arg Phe Thr Leu Gly Thr Val Leu Gly Leu Ala Thr Leu His
 320 325 330

acc tac cgc gga cgc ctc tcc tac ctc ccc gcc act gtg gaa cct gcc 1056
 Thr Tyr Arg Gly Arg Leu Ser Tyr Leu Pro Ala Thr Val Glu Pro Ala
 335 340 345 350

tgc ccc acc cct gcc cat agc ctg cct cgt gcc aag tgc gag ctg acc 1104
 Ser Pro Thr Pro Ala His Ser Leu Pro Arg Ala Lys Ser Glu Leu Thr

355	380	365	
cta acc cca gac cca gcc ccc atg gcc cac tca ccc ctg cat cgt			1152
Leu Thr Pro Asp Pro Ala Pro Pro Met Ala His Ser Pro Leu His Arg			
370	375	380	
tet gtg tct gac ctg cct ett ccc ctg ccc cag cct gcc ctg gcc tet			1200
Ser Val Ser Asp Leu Pro Leu Pro Leu Pro Gln Pro Ala Leu Ala Ser			
385	390	395	
cct gcc tcg cca gaa ccc ctg ccc atc ctg tcc ctc aac ggt ggg gcc			1248
Pro Gly Ser Pro Glu Pro Leu Pro Ile Leu Ser Leu Asn Gly Gly Gly			
400	405	410	
cca gag ctg gct ggg gac tgg ggt ggg gct ggg gat gct ccg ctg tcc			1296
Pro Glu Leu Ala Gly Asp Trp Gly Gly Ala Gly Asp Ala Pro Leu Ser			
415	420	425	430
ccg gac cca ctg ctg tct tca cct cct gcc tct ccc aag gca gct cta			1344
Pro Asp Pro Leu Leu Ser Ser Pro Pro Gly Ser Pro Lys Ala Ala Leu			
435	440	445	
cac tca ccc gtc tcc gaa ggg gcc ccc gta att ccc cca tcc tct ggg			1392
His Ser Pro Val Ser Glu Gly Ala Pro Val Ile Pro Pro Ser Ser Gly			
450	455	460	
ctc cca ctt ccc acc cct gat gcc cgg gta ggg gcc tcc acc tgc gcc			1440
Leu Pro Leu Pro Thr Pro Asp Ala Arg Val Gly Ala Ser Thr Cys Gly			
465	470	475	
ccg ccc gac cac ctg ctg cct ccg ctg gcc acc ccg ctg ccc cca gac			1488
Pro Pro Asp His Leu Leu Pro Pro Leu Gly Thr Pro Leu Pro Pro Asp			
480	485	490	
tgg gtg acg ctg gag ggg gac ttt gtg ctc atg ttg gcc atc tcg ccc			1536
Trp Val Thr Leu Glu Gly Asp Phe Val Leu Met Leu Ala Ile Ser Pro			
495	500	505	510

ago cac cta ggc gct gac ctg gtg gca gct ccg cat gcg cgc ttc gac 1584
 Ser His Leu Gly Ala Asp Leu Val Ala Ala Pro His Ala Arg Phe Asp
 515 520 525

gac ggc ctg gtg cac ctg tgc tgg gtg cgt agc ggc atc teg egg gct 1632
 Asp Gly Leu Val His Leu Cys Trp Val Arg Ser Gly Ile Ser Arg Ala
 530 535 540

gcg ctg ctg cgc ctt ttc ttg gcc atg gag cgt ggt agc cac ttc agc 1680
 Ala Leu Leu Arg Leu Phe Leu Ala Met Glu Arg Gly Ser His Phe Ser
 545 550 555

ctg ggc tgt ccg cag ctg ggc tac gcc ggc gcc cgt gcc ttc cgc cta 1728
 Leu Gly Cys Pro Gln Leu Gly Tyr Ala Ala Ala Arg Ala Phe Arg Leu
 560 565 570

gag cgg ctc aca cca cgc ggc gtg ctc aca gtg gac ggg gag cag gtg 1776
 Glu Pro Leu Thr Pro Arg Gly Val Leu Thr Val Asp Gly Glu Gln Val
 575 580 585 590

gag tat ggg cgg cta cag gca cag atg cac cct ggc atc ggt aca ctg 1824
 Glu Tyr Gly Pro Leu Gln Ala Gln Met His Pro Gly Ile Gly Thr Leu
 595 600 605

ctc act ggg cct cct ggc tgc cgg ggg cgg gag ccc tgaaactaaa 1870
 Leu Thr Gly Pro Pro Gly Cys Pro Gly Arg Glu Pro
 610 615

caagcttggg acccgccggg ggcggggcct acattccaat gggcgaggagc ttgagctagg 1930

ggggtgtggcc tggtgtctag agttgtggtg gcaggzggccc tggccccgto tcaggattgc 1990

gctcgctttc atgggaccag acgtgatgct ggaaggtggg cgtcgtcacg gttaaagaga 2050

aatgggctcg tcccgagggt agtgccctgat caatgagggc ggggcctggc gtctgatctg 2110

gggccgccct tacggggcag ggctcagtcg tgacgcttgc cactgctcc taccgggcca 2170

ggatggctga gggcggagtc tattttacgc gtgcgccaat gacaggacct ggaatgtact 2230

ggctgggta ggcctcagtg agtcggcgg tcagggcccg cagctogcc ccatacactc 2290

egtgccctcc atttagctgg ccaatcagcc caggaggggc aggtccccc gggccgccc 2350

taggatttgc actaatgttc ctctccccc 2380

<210> 14

<211> 618

<212> PRT

<213> Homo sapiens

<400> 14

Met Ala Pro Pro Pro Pro Pro Leu Ala Ala Ser Thr Pro Leu Leu His
1 5 10 15

Gly Glu Phe Gly Ser Tyr Pro Ala Arg Gly Pro Arg Phe Ala Leu Thr
20 25 30

Leu Thr Ser Gln Ala Leu His Ile Gln Arg Leu Arg Pro Lys Pro Glu
35 40 45

Ala Arg Pro Arg Gly Gly Leu Val Pro Leu Ala Glu Val Ser Gly Cys
50 55 60

Gys Thr Leu Arg Ser Arg Ser Pro Ser Asp Ser Ala Ala Tyr Phe Cys
65 70 75 80

Ile Tyr Thr Tyr Pro Arg Gly Arg Arg Gly Ala Arg Arg Arg Ala Thr
85 90 95

Arg Thr Phe Arg Ala Asp Gly Ala Ala Thr Tyr Glu Glu Asn Arg Ala
100 105 110

Glu Ala Gln Arg Trp Ala Thr Ala Leu Thr Cys Leu Leu Arg Gly Leu
115 120 125

Pro Leu Pro Gly Asp Gly Glu Ile Thr Pro Asp Leu Leu Pro Arg Pro
 130 135 140

Pro Arg Leu Leu Leu Leu Val Asn Pro Phe Gly Gly Arg Gly Leu Ala
 145 150 155 160

Trp Gln Trp Cys Lys Asn His Val Leu Pro Met Ile Ser Glu Ala Gly
 165 170 175

Leu Ser Phe Asn Leu Ile Gln Thr Glu Arg Gln Asn His Ala Arg Glu
 180 185 190

Leu Val Gln Gly Leu Ser Leu Ser Glu Trp Asp Gly Ile Val Thr Val
 195 200 205

Ser Gly Asp Gly Leu Leu His Glu Val Leu Asn Gly Leu Leu Asp Arg
 210 215 220

Pro Asp Trp Glu Glu Ala Val Lys Met Pro Val Gly Ile Leu Pro Cys
 225 230 235 240

Gly Ser Gly Asn Ala Leu Ala Gly Ala Val Asn Gln His Gly Gly Phe
 245 250 255

Glu Pro Ala Leu Gly Leu Asp Leu Leu Leu Asn Cys Ser Leu Leu Leu
 260 265 270

Cys Arg Gly Gly Gly His Pro Leu Asp Leu Leu Ser Val Thr Leu Ala
 275 280 285

Ser Gly Ser Arg Cys Phe Ser Phe Leu Ser Val Ala Trp Gly Phe Val
 290 295 300

Ser Asp Val Asp Ile Gln Ser Glu Arg Phe Arg Ala Leu Gly Ser Ala
 305 310 315 320

Arg Phe Thr Leu Gly Thr Val Leu Gly Leu Ala Thr Leu His Thr Tyr

	325		330		335
Arg Gly Arg Leu Ser Tyr Leu Pro Ala Thr Val Glu Pro Ala Ser Pro					
	340		345		350
Thr Pro Ala His Ser Leu Pro Arg Ala Lys Ser Glu Leu Thr Leu Thr					
	355		360		365
Pro Asp Pro Ala Pro Pro Met Ala His Ser Pro Leu His Arg Ser Val					
	370		375		380
Ser Asp Leu Pro Leu Pro Leu Pro Gln Pro Ala Leu Ala Ser Pro Gly					
385		390		395	400
Ser Pro Glu Pro Leu Pro Ile Leu Ser Leu Asn Gly Gly Gly Pro Glu					
	405		410		415
Leu Ala Gly Asp Trp Gly Gly Ala Gly Asp Ala Pro Leu Ser Pro Asp					
	420		425		430
Pro Leu Leu Ser Ser Pro Pro Gly Ser Pro Lys Ala Ala Leu His Ser					
	435		440		445
Pro Val Ser Glu Gly Ala Pro Val Ile Pro Pro Ser Ser Gly Leu Pro					
	450		455		460
Leu Pro Thr Pro Asp Ala Arg Val Gly Ala Ser Thr Cys Gly Pro Pro					
465		470		475	480
Asp His Leu Leu Pro Pro Leu Gly Thr Pro Leu Pro Pro Asp Trp Val					
	485		490		495
Thr Leu Glu Gly Asp Phe Val Leu Met Leu Ala Ile Ser Pro Ser His					
	500		505		510
Leu Gly Ala Asp Leu Val Ala Ala Pro His Ala Arg Phe Asp Asp Gly					
	515		520		525

Leu Val His Leu Cys Trp Val Arg Ser Gly Ile Ser Arg Ala Ala Leu
 530 535 540

Leu Arg Leu Phe Leu Ala Met Glu Arg Gly Ser His Phe Ser Leu Gly
 545 550 555 560

Cys Pro Gln Leu Gly Tyr Ala Ala Ala Arg Ala Phe Arg Leu Glu Pro
 565 570 575

Leu Thr Pro Arg Gly Val Leu Thr Val Asp Gly Glu Gln Val Glu Tyr
 580 585 590

Gly Pro Leu Gln Ala Gln Met His Pro Gly Ile Gly Thr Leu Leu Thr
 595 600 605

Gly Pro Pro Gly Cys Pro Gly Arg Glu Pro
 610 615

<210> 15

<211> 388

<212> PRT

<213> Mus musculus

<300>

<302> Molecular cloning and functional characterization of
 murine sphingosine kinase

<303> J. Biol. Chem.

<304> 273

<305> 37

<306> 23722-23728

<308> AAC81898

<400> 15

Met Trp Trp Cys Cys Val Leu Phe Val Val Glu Cys Pro Arg Gly Leu
 1 5 10 15

Leu Pro Arg Pro Cys Arg Val Leu Val Leu Leu Asn Pro Gln Gly Gly

	20		25		30
Lys Gly Lys Ala Leu Gln Leu Phe Gln Ser Arg Val Gln Pro Phe Leu					
	35		40		45
Glu Glu Ala Glu Ile Thr Phe Lys Leu Ile Leu Thr Glu Arg Lys Asn					
	50		55		60
His Ala Arg Glu Leu Val Cys Ala Glu Glu Leu Gly His Trp Asp Ala					
	65		70		75
					80
Leu Ala Val Met Ser Gly Asp Gly Leu Met His Glu Val Val Asn Gly					
		85		90	95
Leu Met Glu Arg Pro Asp Trp Glu Thr Ala Ile Gln Lys Pro Leu Cys					
	100		105		110
Ser Leu Pro Gly Gly Ser Gly Asn Ala Leu Ala Ala Ser Val Asn His					
	115		120		125
Tyr Ala Gly Tyr Glu Gln Val Thr Asn Glu Asp Leu Leu Ile Asn Cys					
	130		135		140
Thr Leu Leu Leu Cys Arg Arg Arg Leu Ser Pro Met Asn Leu Leu Ser					
	145		150		155
					160
Leu His Thr Ala Ser Gly Leu Arg Leu Tyr Ser Val Leu Ser Leu Ser					
		165		170	175
Trp Gly Phe Val Ala Asp Val Asp Leu Glu Ser Glu Lys Tyr Arg Arg					
	180		185		190
Leu Gly Glu Ile Arg Phe Thr Val Gly Thr Phe Phe Arg Leu Ala Ser					
	195		200		205
Leu Arg Ile Tyr Gln Gly Gln Leu Ala Tyr Leu Pro Val Gly Thr Val					
	210		215		220

Ala Ser Lys Arg Pro Ala Ser Thr Leu Val Gln Lys Gly Pro Val Asp
 225 230 235 240

Thr His Leu Val Pro Leu Glu Glu Pro Val Pro Ser His Trp Thr Val
 245 250 255

Val Pro Glu Gln Asp Phe Val Leu Val Leu Val Leu Leu His Thr His
 260 265 270

Leu Ser Ser Glu Leu Phe Ala Ala Pro Met Gly Arg Cys Glu Ala Gly
 275 280 285

Val Met His Leu Phe Tyr Val Arg Ala Gly Val Ser Arg Ala Ala Leu
 290 295 300

Leu Arg Leu Phe Leu Ala Met Gln Lys Gly Lys His Met Glu Leu Asp
 305 310 315 320

Cys Pro Tyr Leu Val His Val Pro Val Val Ala Phe Arg Leu Glu Pro
 325 330 335

Arg Ser Gln Arg Gly Val Phe Ser Val Asp Gly Glu Leu Met Val Cys
 340 345 350

Glu Ala Val Gln Gly Gln Val His Pro Asn Tyr Leu Trp Met Val Cys
 355 360 365

Gly Ser Arg Asp Ala Pro Ser Gly Arg Asp Ser Arg Arg Gly Pro Pro
 370 375 380

Pro Glu Glu Pro
 385

It will be appreciated that the instant specification is set forth by way of illustration and not limitation, and that various modifications and changes may be made without departing from the spirit and scope of the present invention.

Applicant's or agent's file reference	00170PCT/HG	International application No.	PCT/US 01/09664
--	-------------	-------------------------------	-----------------

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>18</u> , line <u>27 to 33</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology	
Address of depositary institution (including postal code and country) 1-3, Higashi 1-chome Tsukuba-shi, Ibaraki-ken 305-8566	
Date of deposit March 29, 2000	Accession Number FERM BP-7110
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer S R. Hostad	Authorized officer

WHAT IS CLAIMED IS:

1. An isolated and purified DNA which encodes a mammalian sphingosine kinase type 2 isoform.
2. The isolated and purified DNA of claim 1, which encodes a mouse sphingosine kinase type 2 isoform DNA.
3. The isolated and purified DNA of claim 1, which encodes a human sphingosine kinase type 2 isoform DNA.
4. The isolated and purified DNA of claim 2, which encodes a peptide of 617 amino acids.
5. The isolated and purified DNA of claim 3, which encodes a peptide of 618 amino acids.
6. A peptide encoded by the DNA of claim 4.
7. A peptide encoded by the DNA of claim 5.
8. An amino acid sequence of human SPHK2 consisting essentially of SEQ ID NO: 14.
9. An amino acid sequence of murine SPHK2 consisting essentially of SEQ ID NO: 12.
10. An isolated and purified DNA which encodes a peptide of a sphingosine kinase type 2 isoform, said DNA comprising a sequence selected from the group consisting of the sequence of Genbank Accession No. nkit325787 and the sequence of Genbank Accession No. bankit325752.
11. A recombinant DNA construct comprising:
 - (a) a vector and
 - (b) the DNA of claim 2.

12. A recombinant DNA construct comprising:
 - (a) a vector and
 - (b) the DNA of claim 3.
13. The recombinant DNA construct according to claim 11, wherein said vector is an expression vector.
14. The recombinant DNA construct according to claim 11, wherein said vector is a prokaryotic vector.
15. The recombinant DNA construct according to claim 11, wherein said vector is a eukaryotic vector.
16. The recombinant DNA construct according to claim 12, wherein said vector is an expression vector.
17. The recombinant DNA construct according to claim 12, wherein said vector is a prokaryotic vector.
18. The recombinant DNA construct according to claim 12, wherein said vector is a eukaryotic vector.
19. A host cell transformed with the recombinant DNA construct according to claim 11.
20. The host cell according to claim 19, wherein said cell is prokaryotic.
21. The host cell according to claim 19, wherein said cell is eukaryotic.
22. A host cell transformed with the recombinant DNA construct according to claim 12.

23. The host cell according to claim 22, wherein said cell is prokaryotic.

24. The host cell according to claim 22, wherein said cell is eukaryotic.

25. A method for producing a mouse sphingosine kinase type 2 isoform peptide which comprises culturing the host cell according to claim 19, under conditions such that an isolated mouse sphingosine kinase type 2 isoform DNA is expressed and said mouse sphingosine kinase type 2 isoform peptide is thereby produced.

26. A method for producing a human sphingosine kinase type 2 isoform peptide which comprises culturing the host cell according to claim 22, under conditions such that an isolated human sphingosine kinase type 2 isoform DNA is expressed and said human sphingosine kinase type 2 isoform peptide is thereby produced.

27. A method for detecting an agent or a drug which inhibits or promotes sphingosine kinase type 2 activity comprising:

(a) providing a recombinant DNA construct according to claim 11, into a cell such that sphingosine kinase type 2 isoform is produced in said cell;

(b) adding at least one drug or agent to said cell, and

(c) detecting whether or not said drug or agent inhibits or promotes sphingosine kinase type 2 activity by measuring sphingosine kinase-dependent phosphorylation of lipids in said cells and comparing the resultant measurement to a control which did not receive said drug or agent, wherein a decrease in the amount of sphingosine kinase-dependent phosphorylation of lipids as compared to the control indicates an inhibitory drug or agent, or an increase in the amount of sphingosine

kinase-dependent phosphorylation of lipids in said cell as compared to the control indicates a stimulatory drug or agent.

28. A method for detecting an agent or a drug which inhibits or promotes sphingosine kinase type 2 activity comprising:

(a) providing a recombinant DNA construct according to claim 12, into a cell such that sphingosine kinase type 2 isoform is produced in said cell;

(b) adding at least one drug or agent to said cell, and

(c) detecting whether or not said drug or agent inhibits or promotes sphingosine kinase type 2 activity by measuring sphingosine kinase-dependent phosphorylation of lipids in said cells and comparing the resultant measurement to a control which did not receive said drug or agent, wherein a decrease in the amount of sphingosine kinase-dependent phosphorylation of lipids as compared to the control indicates an inhibitory drug or agent, or an increase in the amount of sphingosine kinase-dependent phosphorylation of lipids in said cell as compared to the control indicates a stimulatory drug or agent.

29. An agent or drug detected by the method of claim 27.

30. An agent or drug detected by the method of claim 28.

31. A method of regulating a biological process in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of the peptide according to claim 6.

32. A method of regulating a biological process in a mammal comprising administering to a mammal in need thereof a pharmaceutically effective amount of the peptide according to claim 7.

33. The method of claim 31, wherein the biological process is selected from the group consisting of mitogenesis, apoptosis, neuronal development, chemotaxis, angiogenesis and inflammatory responses.

34. The method of claim 31, wherein the biological process is angiogenesis.

35. The method of claim 32, wherein the biological process is selected from the group consisting of mitogenesis, apoptosis, neuronal development, chemotaxis, angiogenesis and inflammatory responses.

36. The method of claim 32, wherein the biological process is angiogenesis.

37. A method for the treatment or amelioration of a disease resulting from increased cell death or decreased cell proliferation, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a peptide according to claim 6.

38. A method for the treatment or amelioration of a disease resulting from increased cell death or decreased cell proliferation, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a peptide according to claim 7.

39. A method for the treatment or administration of a disease resulting from decreased cell death or increased cell proliferation comprising administering to a mammal in need thereof a pharmaceutically effective amount of an antibody to a peptide according to claim 6.

40. A method for the treatment or administration of a disease resulting from decreased cell death or increased cell proliferation comprising administering to a mammal in need thereof a pharmaceutically effective amount of an antibody to a peptide according to claim 7.

41. A method for the treatment or amelioration of a disease resulting from abnormal migration or motility of cells selected from the group consisting of cancer, restenosis and diabetic neuropathy, the method comprising administering to a mammal in need thereof, a pharmaceutically effective amount of an antibody to a peptide according to claim 6.

42. A method for the treatment or amelioration of a disease resulting from abnormal migration or motility of cells selected from the group consisting of cancer, restenosis and diabetic neuropathy, the method comprising administering to a mammal in need thereof, a pharmaceutically effective amount of an antibody to a peptide according to claim 7.

43. The method of claim 41, wherein the disease is cancer.

44. The method of claim 42, wherein the disease is cancer.

45. A composition for treating or ameliorating a disease resulting from increased cell death or decreased cell proliferation comprising a pharmaceutically effective amount of a peptide according to claim 6, and a pharmaceutically acceptable carrier.

46. A composition for treating or ameliorating a disease resulting from increased cell death or decreased cell proliferation comprising a pharmaceutically effective amount

of a peptide according to claim 7, and a pharmaceutically acceptable carrier.

47. A method for screening agents or drugs which reduce or eliminate sphingosine kinase type 2 activity, the method comprising detecting a decrease in sphingosine kinase type 2 enzyme activity in the presence of said agent or drug.

48. A method for detecting the presence of a sphingosine kinase type 2 isoform in a sample comprising

(i) contacting a sample with antibodies which recognize sphingosine kinase type 2; and

(ii) detecting the presence or absence of a complex formed between sphingosine kinase type 2 and antibodies specific therefor.

49. A method for detecting sphingosine kinase type 2 in a sample comprising subjecting the sample to a polymerase chain reaction and detecting for the presence of sphingosine kinase type 2.

50. A diagnostic kit for detecting sphingosine kinase type 2 RNA/cDNA in a sample comprising primers or oligonucleotides specific for sphingosine kinase type 2 RNA or cDNA suitable for hybridization to sphingosine kinase type 2 RNA or cDNA and/or amplification of sphingosine kinase type 2 sequences and suitable ancillary reagents.




FIG.1A-1

mSPHK1	370	380	390	400	410	420
mSPHK2	RAKSELV	LA	PAP	AAT	HSPL	HR
hSPHK2	RAKSELV	LA	PAP	AAT	HSPL	HR
mSPHK1	430	440	450	460	470	480
mSPHK2	DWGGAGDA	PLSPDP	LLPSS	PNAL	KT	AQL
hSPHK2	DWGGAGDA	PLSPDP	LLPSS	PNAL	KT	AQL
mSPHK1	490	500	510	520	530	540
mSPHK2	VDT	HL	VPL	EE	PV	PP
hSPHK2	VDT	HL	VPL	EE	PV	PP
mSPHK1	550	560	570	580	590	600
mSPHK2	VSR	A	ALL	R	L	F
hSPHK2	VSR	A	ALL	R	L	F
mSPHK1	610	620	630			
mSPHK2	VHP	N	Y	L	W	M
hSPHK2	VHP	N	Y	L	W	M

C5

FIG.1A-1
FIG.1A-2

FIG.1A

FIG.1A-2

3/11






FIG.1B

4/11



5/11




FIG.3A




FIG.3B

6/11




FIG.4A




FIG.4B

7/11




FIG.4C




FIG.4D

8/11




FIG.5A




FIG.5B

9/11




FIG.5C




FIG.5D




FIG. 5E




FIG. 6A

11/11




FIG.6B




FIG.6C

SEQUENCE LISTING

<110> SANKYO COMPANY, LIMITED
GEORGETOWN UNIVERSITY

<120> Mammalian Sphingosine Kinase Type 2 Isoforms, Cloning,
Expression and Methods of Use Thereof

<130> 00170PCT/HG

<140>

<141>

<150> US 60/194,318

<151> 2000-04-03

<160> 15

<170> PatentIn Ver. 2.0

<210> 1

<211> 26

<212> DNA

<213> Mus musculus

<400> 1

cctgggtgca cctg'gcctg tattgg

26

<210> 2

<211> 24

<212> DNA

<213> Mus musculus

<400> 2

ccagtcttgg ggcagtggag agcc

24

2/23

<210> 3

<211> 16

<212> DNA

<213> Mus musculus

<400> 3

aggtagaggc ttotgg

16

<210> 4

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 5' RACE
Abridged Anchor Primer

<220>

<221> modified_base

<222> (24).. (25)

<223> i

<220>

<221> modified_base

<222> (29).. (30)

<223> i

<220>

<221> modified_base

<222> (34).. (35)

<223> i

<400> 4

ggccacgcgt cgactagtac gggnnngggnn gggnnng

36

<210> 5

3/23

<211> 22

<212> DNA

<213> Mus musculus

<400> 5

gcgatgggtg aaagotgagc tg

22

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Abridged
Universal Amplification Primer

<400> 6

ggccacgcgt cgactagtac

20

<210> 7

<211> 22

<212> DNA

<213> Mus musculus

<400> 7

agtctccagt cagctctgga cc

22

<210> 8

<211> 16

<212> DNA

<213> Homo sapiens

<400> 8

cccactcact caggct

16

4/23

<210> 9

<211> 22

<212> DNA

<213> Homo sapiens

<400> 9

gaaggacagc ccagcttcag ag

22

<210> 10

<211> 20

<212> DNA

<213> Homo sapiens

<400> 10

attgaccaat agaagcaacc

20

<210> 11

<211> 2698

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (387).. (2237)

<300>

<302> Molecular cloning and functional characterization of a
novel mammalian sphingosine kinase type 2 isoform

<303> J. Biol. Chem.

<304> 275

<305> 26

<306> 19513-19520

<308> AF245448

<400> 11

5/23

aattcggcac gagggaggac cgagtaaacc gaggcctcca gaaccaaaga gaagtcagcc 60
tgaggaaagg gctgggaccc ggagcctctc tggcctttcc ccgtccctgc tctaacactc 120
tccaggggta aagggaccgg agaatcagag acatgatcgg agcttgctgg acgagtgcg 180
tggtgactct ctggccgcac gccgaccgct tctcgggtggc tcgaggagga cccgggtggc 240
tgtgtgtcgg agcctccgaa gtagctggaa tcaccgtctt tcaacaattg gcctggctct 300
gccatttaaa gttgtgatct tggaggctgg tccaggagct gaccacaagc caagagoccta 360

ggagtgcctg ggactgaacc agggtc atg gcc cca cca cca cta ctg cca gtg 413
Met Ala Pro Pro Pro Leu Leu Pro Val
1 5

gct gcc agc act cca atc ctg cac ggc gag ttt ggt tcc tac ccg gcc 461
Ala Ala Ser Thr Pro Ile Leu His Gly Glu Phe Gly Ser Tyr Pro Ala
10 15 20 25

aac ggc cca cgg ttt gcc ctc acc ctc aca aca caa gcc cta cac ata 509
Asn Gly Pro Arg Phe Ala Leu Thr Leu Thr Thr Gln Ala Leu His Ile
30 35 40

cag cga cta cgc cca aag cca gaa gcc cgg ccc cga gat ggt cta gtc 557
Gln Arg Leu Arg Pro Lys Pro Glu Ala Arg Pro Arg Asp Gly Leu Val
45 50 55

tct ctg gat gag gtc tcg ggc tgt ggc acc ctg cag agc cgt agc ccc 605
Ser Leu Asp Glu Val Ser Gly Cys Gly Thr Leu Gln Ser Arg Ser Pro
60 65 70

gag gac act gca gcc tac ttc tgc atc tac acc tac cca cgt ggc cgt 653
Glu Asp Thr Ala Ala Tyr Phe Cys Ile Tyr Thr Tyr Pro Arg Gly Arg
75 80 85

oga ggg ggc cgg cgc aga gct acg cgg acc ttc cgg gcg gat ggg gcc 701
Arg Gly Gly Arg Arg Arg Ala Thr Arg Thr Phe Arg Ala Asp Gly Ala

6/23

90	95	100	105	
acc act tat gag gag aat cgt gca gag gcc cag cgc tgg gcc act gcc				749
Thr Thr Tyr Glu Glu Asn Arg Ala Glu Ala Gln Arg Trp Ala Thr Ala				
	110	115	120	
ctc acg tgt ctc ctc cga gga gtg cct ctg tca ggg gac cag gaa atc				797
Leu Thr Cys Leu Leu Arg Gly Val Pro Leu Ser Gly Asp Gln Glu Ile				
	125	130	135	
acc cct gaa ttg ctg ccc cgg aag ccc agg ctg ctc ata ttg gtc aat				845
Thr Pro Glu Leu Leu Pro Arg Lys Pro Arg Leu Leu Ile Leu Val Asn				
	140	145	150	
ccc ttt ggg ggg cgg ggc ctg gcc tgg cag cgc tgt atg gac cac gtg				893
Pro Phe Gly Gly Arg Gly Leu Ala Trp Gln Arg Cys Met Asp His Val				
	155	160	165	
gtg cca atg atc tct gaa gct ggg ctg tcc ttc aac ctc ata cag aca				941
Val Pro Met Ile Ser Glu Ala Gly Leu Ser Phe Asn Leu Ile Gln Thr				
170	175	180	185	
gaa cga cag aac cat gcc cgt gag ctg gtg cag ggg tta ago ctg agt				989
Glu Arg Gln Asn His Ala Arg Glu Leu Val Gln Gly Leu Ser Leu Ser				
	190	195	200	
gag tgg gaa ggc att gtc act gtg tot gga gac ggg ctg ott tac gag				1037
Glu Trp Glu Gly Ile Val Thr Val Ser Gly Asp Gly Leu Leu Tyr Glu				
	205	210	215	
gtg ctg aat ggg ctc ott gat cgg cca gac tgg gag gat gcc gtg cgg				1085
Val Leu Asn Gly Leu Leu Asp Arg Pro Asp Trp Glu Asp Ala Val Arg				
	220	225	230	
atg ccc att ggt gtc ctc ccc tgt gga tgg ggc aat gcg cta gct ggg				1133
Met Pro Ile Gly Val Leu Pro Cys Gly Ser Gly Asn Ala Leu Ala Gly				
	235	240	245	

7/23

gcg gtg agc cat cat ggc ggg ttt gag cag gtt gtc ggt gtt gac ctg 1181
 Ala Val Ser His His Gly Gly Phe Glu Gln Val Val Gly Val Asp Leu
 250 255 260 265

ttg ctc aac tgc tcg ctt ctt ctc tgc cgt ggt ggc agc cat cct ctg 1229
 Leu Leu Asn Cys Ser Leu Leu Leu Cys Arg Gly Gly Ser His Pro Leu
 270 275 280

gac ttg ctc tot gtg acg cta gcc tcg gga tcc cgc tgt ttt tcc ttc 1277
 Asp Leu Leu Ser Val Thr Leu Ala Ser Gly Ser Arg Cys Phe Ser Phe
 285 290 295

ctg tca gtg gcc tgg gga ttc ttg tca gat gtg gac att cac agt gag 1325
 Leu Ser Val Ala Trp Gly Phe Leu Ser Asp Val Asp Ile His Ser Glu
 300 305 310

cgc ttc agg gcc ctg ggc agc gct cga ttc aca ctg ggt gca gtg cta 1373
 Arg Phe Arg Ala Leu Gly Ser Ala Arg Phe Thr Leu Gly Ala Val Leu
 315 320 325

ggc ctg gcc tog ttg cat acc tac cgt gga cgc ctc tcc tac ctc ccc 1421
 Gly Leu Ala Ser Leu His Thr Tyr Arg Gly Arg Leu Ser Tyr Leu Pro
 330 335 340 345

gct acc aca gaa cca gcc ttg ccc atc cca gcc cac agt ctg cct cga 1469
 Ala Thr Thr Glu Pro Ala Leu Pro Ile Pro Gly His Ser Leu Pro Arg
 350 355 360

gcc aag tca gaa cta gtc ttg gct cca gcc cca gcc ccc gcc gcc acc 1517
 Ala Lys Ser Glu Leu Val Leu Ala Pro Ala Pro Ala Pro Ala Ala Thr
 365 370 375

cac tcg cct cta cat cga tct gtg tot gac ctg ccc ctg ccc ctt ccc 1565
 His Ser Pro Leu His Arg Ser Val Ser Asp Leu Pro Leu Pro Leu Pro
 380 385 390

cag cct gcc ttg gtc tcc cct ggc tcc cct gag ccc ctg cct gac ctg 1613
 Gln Pro Ala Leu Val Ser Pro Gly Ser Pro Glu Pro Leu Pro Asp Leu

8/23

395	400	405	
tcc ctc aat ggt ggt ggt cca gag ctg act gga gac tgg gga gga gct			1661
Ser Leu Asn Gly Gly Gly Pro Glu Leu Thr Gly Asp Trp Gly Gly Ala			
410	415	420	425
ggg gat gca cct ctg tcc cca gac cca ctg ctg cct tca tcc ccc aac			1709
Gly Asp Ala Pro Leu Ser Pro Asp Pro Leu Leu Pro Ser Ser Pro Asn			
	430	435	440
gct ctc aaa aca gct cag ctt tca ccc atc gct gaa ggg ccc cca gaa			1757
Ala Leu Lys Thr Ala Gln Leu Ser Pro Ile Ala Glu Gly Pro Pro Glu			
	445	450	455
atg cca gca tct tcg ggg ttc ctg cct ccc acc cac agt gcc cca gaa			1805
Met Pro Ala Ser Ser Gly Phe Leu Pro Pro Thr His Ser Ala Pro Glu			
	460	465	470
gcc tct acc tgg ggc cca gtg gac cac ctc ctc cct ccc ctg ggc tct			1853
Ala Ser Thr Trp Gly Pro Val Asp His Leu Leu Pro Pro Leu Gly Ser			
	475	480	485
cca ctg ccc caa gac tgg gtg aca ata gag ggg gag ttt gta ctc atg			1901
Pro Leu Pro Gln Asp Trp Val Thr Ile Glu Gly Glu Phe Val Leu Met			
	490	495	500
ttg ggc atc ttg acg agc cac ctc tgc gca gac ctg atg gca gcc cca			1949
Leu Gly Ile Leu Thr Ser His Leu Cys Ala Asp Leu Met Ala Ala Pro			
	510	515	520
cat gca cgc ttt gat gat ggc gtt gtg cac ctg tgt tgg gtg cgg agc			1997
His Ala Arg Phe Asp Asp Gly Val Val His Leu Cys Trp Val Arg Ser			
	525	530	535
ggc atc tca cgg gct gca ctt cta cgc att ttt ctg gcc atg gag cat			2045
Gly Ile Ser Arg Ala Ala Leu Leu Arg Ile Phe Leu Ala Met Glu His			
	540	545	550

9/23

gga aac cac ttc agc ctg ggc tgc ccc cat ctg ggc tat gct gca gca 2093
 Gly Asn His Phe Ser Leu Gly Cys Pro His Leu Gly Tyr Ala Ala Ala
 555 560 565

cgt gcc ttc cgc ctt gaa cca ctc acg cct cgt ggc ctg ctc act gta 2141
 Arg Ala Phe Arg Leu Glu Pro Leu Thr Pro Arg Gly Leu Leu Thr Val
 570 575 580 585

gat ggg gag tta gtg gag tat ggg cca ata cag gcg cag gtg cac cca 2189
 Asp Gly Glu Leu Val Glu Tyr Gly Pro Ile Gln Ala Gln Val His Pro
 590 595 600

ggt ctc gcc acg ctg ctc act ggg cct gca ggt caa aag cca caa gcc 2237
 Gly Leu Ala Thr Leu Leu Thr Gly Pro Ala Gly Gln Lys Pro Gln Ala
 605 610 615

tgaacgagcc taaaagcatg gcgagttggt ggaaccagcg ccccataggc taagatctat 2297

catttacagg tagaagtggg gcccgcactc agaactgtga ggagggtgga gagggtcct 2357

gacctcagt tccagagga octagaggct cgagggtggg gcctgccttt cttgatgtcc 2417

aatgatgggg octggaatgt atgagctagc aaggcttctt cagcttattg accagocagg 2477

gtttcttctt gcctactccg gtgcctctac ttgactggcc aatcagccct tgaggggcag 2537

gttccccag gtggtcccca gatttgcaact aatgttctc cctggccag ttagggatgg 2597

gatgttctgt gtcttgtgtg tccctctccc tagtctaaaa agcaattgaa aaggtctatg 2657

caataaaggt tgttgcttcc ctctaaaaaa aaaaaaaaaa a 2698

<210> 12

<211> 617

<212> PRT

<213> Mus musculus

10/23

<400> 12

Met Ala Pro Pro Pro Leu Leu Pro Val Ala Ala Ser Thr Pro Ile Leu
1 5 10 15

His Gly Glu Phe Gly Ser Tyr Pro Ala Asn Gly Pro Arg Phe Ala Leu
20 25 30

Thr Leu Thr Thr Gln Ala Leu His Ile Gln Arg Leu Arg Pro Lys Pro
35 40 45

Glu Ala Arg Pro Arg Asp Gly Leu Val Ser Leu Asp Glu Val Ser Gly
50 55 60

Cys Gly Thr Leu Gln Ser Arg Ser Pro Glu Asp Thr Ala Ala Tyr Phe
65 70 75 80

Cys Ile Tyr Thr Tyr Pro Arg Gly Arg Arg Gly Gly Arg Arg Arg Ala
85 90 95

Thr Arg Thr Phe Arg Ala Asp Gly Ala Thr Thr Tyr Glu Glu Asn Arg
100 105 110

Ala Glu Ala Gln Arg Trp Ala Thr Ala Leu Thr Cys Leu Leu Arg Gly
115 120 125

Val Pro Leu Ser Gly Asp Gln Glu Ile Thr Pro Glu Leu Leu Pro Arg
130 135 140

Lys Pro Arg Leu Leu Ile Leu Val Asn Pro Phe Gly Gly Arg Gly Leu
145 150 155 160

Ala Trp Gln Arg Cys Met Asp His Val Val Pro Met Ile Ser Glu Ala
165 170 175

Gly Leu Ser Phe Asn Leu Ile Gln Thr Glu Arg Gln Asn His Ala Arg
180 185 190

Glu Leu Val Gln Gly Leu Ser Leu Ser Glu Trp Glu Gly Ile Val Thr

11/23

195	200	205
Val Ser Gly Asp Gly Leu Leu Tyr Glu Val Leu Asn Gly Leu Leu Asp		
210	215	220
Arg Pro Asp Trp Glu Asp Ala Val Arg Met Pro Ile Gly Val Leu Pro		
225	230	235 240
Cys Gly Ser Gly Asn Ala Leu Ala Gly Ala Val Ser His His Gly Gly		
	245	250 255
Phe Glu Gln Val Val Gly Val Asp Leu Leu Leu Asn Cys Ser Leu Leu		
	260	265 270
Leu Cys Arg Gly Gly Ser His Pro Leu Asp Leu Leu Ser Val Thr Leu		
	275	280 285
Ala Ser Gly Ser Arg Cys Phe Ser Phe Leu Ser Val Ala Trp Gly Phe		
	290	295 300
Leu Ser Asp Val Asp Ile His Ser Glu Arg Phe Arg Ala Leu Gly Ser		
305	310	315 320
Ala Arg Phe Thr Leu Gly Ala Val Leu Gly Leu Ala Ser Leu His Thr		
	325	330 335
Tyr Arg Gly Arg Leu Ser Tyr Leu Pro Ala Thr Thr Glu Pro Ala Leu		
	340	345 350
Pro Ile Pro Gly His Ser Leu Pro Arg Ala Lys Ser Glu Leu Val Leu		
	355	360 365
Ala Pro Ala Pro Ala Pro Ala Ala Thr His Ser Pro Leu His Arg Ser		
	370	375 380
Val Ser Asp Leu Pro Leu Pro Leu Pro Gln Pro Ala Leu Val Ser Pro		
385	390	395 400

12/23

Gly Ser Pro Glu Pro Leu Pro Asp Leu Ser Leu Asn Gly Gly Gly Pro
 405 410 415

Glu Leu Thr Gly Asp Trp Gly Gly Ala Gly Asp Ala Pro Leu Ser Pro
 420 425 430

Asp Pro Leu Leu Pro Ser Ser Pro Asn Ala Leu Lys Thr Ala Gln Leu
 435 440 445

Ser Pro Ile Ala Glu Gly Pro Pro Glu Met Pro Ala Ser Ser Gly Phe
 450 455 460

Leu Pro Pro Thr His Ser Ala Pro Glu Ala Ser Thr Trp Gly Pro Val
 465 470 475 480

Asp His Leu Leu Pro Pro Leu Gly Ser Pro Leu Pro Gln Asp Trp Val
 485 490 495

Thr Ile Glu Gly Glu Phe Val Leu Met Leu Gly Ile Leu Thr Ser His
 500 505 510

Leu Cys Ala Asp Leu Met Ala Ala Pro His Ala Arg Phe Asp Asp Gly
 515 520 525

Val Val His Leu Cys Trp Val Arg Ser Gly Ile Ser Arg Ala Ala Leu
 530 535 540

Leu Arg Ile Phe Leu Ala Met Glu His Gly Asn His Phe Ser Leu Gly
 545 550 555 560

Cys Pro His Leu Gly Tyr Ala Ala Ala Arg Ala Phe Arg Leu Glu Pro
 565 570 575

Leu Thr Pro Arg Gly Leu Leu Thr Val Asp Gly Glu Leu Val Glu Tyr
 580 585 590

Gly Pro Ile Gln Ala Gln Val His Pro Gly Leu Ala Thr Leu Leu Thr
 595 600 605

Gly Pro Ala Gly Gln Lys Pro Gln Ala
 610 615

<210> 13

<211> 2380

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (7).. (1860)

<300>

<302> Molecular cloning and functional characterization of a
 novel mammalian sphingosine kinase type 2 isoform

<303> J. Biol. Chem.

<304> 275

<305> 26

<306> 19513-19520

<308> AF245447

<400> 13

gccacc atg gcc ccg ccc cca ccg cca ctg gct gcc agc acc ccg ctc 48

Met Ala Pro Pro Pro Pro Pro Leu Ala Ala Ser Thr Pro Leu

1 5 10

ctc cat ggc gag ttt ggc tcc tac cca gcc cga ggc cca cgc ttt gcc 96

Leu His Gly Glu Phe Gly Ser Tyr Pro Ala Arg Gly Pro Arg Phe Ala

15 20 25 30

ctc acc ctt aca tcg cag gcc ctg cac ata cag cgg ctg cgc ccc aaa 144

Leu Thr Leu Thr Ser Gln Ala Leu His Ile Gln Arg Leu Arg Pro Lys

35 40 45

cct gaa gcc agg ccc cgg ggt ggc ctg gtc ccg ttg gcc gag gtc tca 192

Pro Glu Ala Arg Pro Arg Gly Gly Leu Val Pro Leu Ala Glu Val Ser

14/23

50	55	60	
ggc tgc tgc acc ctg cga agc cgc agc ccc tca gac tca gcg gcc tac			240
Gly Cys Cys Thr Leu Arg Ser Arg Ser Pro Ser Asp Ser Ala Ala Tyr			
65	70	75	
ttc tgc atc tac acc tac cct cgg ggc cgg cgc ggg gcc cgg cgc aga			288
Phe Cys Ile Tyr Thr Tyr Pro Arg Gly Arg Arg Gly Ala Arg Arg Arg			
80	85	90	
gcc act cgc acc ttc cgg gca gat ggg gcc gcc acc tac gaa gag aac			336
Ala Thr Arg Thr Phe Arg Ala Asp Gly Ala Ala Thr Tyr Glu Glu Asn			
95	100	105	110
ogt gcc gag gcc cag cgc tgg gcc act gcc ctc acc tgt ctg ctc cga			384
Arg Ala Glu Ala Gln Arg Trp Ala Thr Ala Leu Thr Cys Leu Leu Arg			
115	120	125	
gga ctg cca ctg ccc ggg gat ggg gag atc acc cct gac ctg cta cct			432
Gly Leu Pro Leu Pro Gly Asp Gly Glu Ile Thr Pro Asp Leu Leu Pro			
130	135	140	
ogg ccg ccc cgg ttg ott cta ttg gtc aat ccc ttt ggg ggt cgg ggc			480
Arg Pro Pro Arg Leu Leu Leu Leu Val Asn Pro Phe Gly Gly Arg Gly			
145	150	155	
ctg gcc tgg cag tgg tgt aag aac cac gtg ctt ccc atg atc tct gaa			528
Leu Ala Trp Gln Trp Cys Lys Asn His Val Leu Pro Met Ile Ser Glu			
160	165	170	
got ggg ctg tcc ttc aac ctc atc cag aca gaa cga cag aac cac gcc			576
Ala Gly Leu Ser Phe Asn Leu Ile Gln Thr Glu Arg Gln Asn His Ala			
175	180	185	190
ogg gag ctg gtc cag ggg ctg ago ctg agt gag tgg gat ggc atc gtc			624
Arg Glu Leu Val Gln Gly Leu Ser Leu Ser Glu Trp Asp Gly Ile Val			
195	200	205	

15/23

acg gtc tog gga gac ggg ctg ctc cat gag gtg ctg aac ggg ctc cta 672
 Thr Val Ser Gly Asp Gly Leu Leu His Glu Val Leu Asn Gly Leu Leu
 210 215 220

gat cgc oct gac tgg gag gaa gct gtg aag atg cct gtg ggc atc ctc 720
 Asp Arg Pro Asp Trp Glu Glu Ala Val Lys Met Pro Val Gly Ile Leu
 225 230 235

ccc tgc ggc tog ggc aac gcg ctg gcc gga gca gtg aac cag cac ggg 768
 Pro Cys Gly Ser Gly Asn Ala Leu Ala Gly Ala Val Asn Gln His Gly
 240 245 250

gga ttt gag cca gcc ctg ggc ctc gac ctg ttg ctc aac tgc tca ctg 816
 Gly Phe Glu Pro Ala Leu Gly Leu Asp Leu Leu Leu Asn Cys Ser Leu
 255 260 265 270

ttg ctg tgc cgg ggt ggt ggc cac cca ctg gac ctg ctc tcc gtg acg 864
 Leu Leu Cys Arg Gly Gly Gly His Pro Leu Asp Leu Leu Ser Val Thr
 275 280 285

ctg gcc tog ggc tcc cgc tgt ttc tcc ttc ctg tct gtg gcc tgg ggc 912
 Leu Ala Ser Gly Ser Arg Cys Phe Ser Phe Leu Ser Val Ala Trp Gly
 290 295 300

ttc gtg tca gat gtg gat atc cag agc gag cgc ttc agg gcc ttg ggc 960
 Phe Val Ser Asp Val Asp Ile Gln Ser Glu Arg Phe Arg Ala Leu Gly
 305 310 315

agt gcc cgc ttc aca ctg ggc acg gtg ctg ggc ctc gcc aca ctg cac 1008
 Ser Ala Arg Phe Thr Leu Gly Thr Val Leu Gly Leu Ala Thr Leu His
 320 325 330

acc tac cgc gga cgc ctc tcc tac ctc ccc gcc act gtg gaa cct gcc 1056
 Thr Tyr Arg Gly Arg Leu Ser Tyr Leu Pro Ala Thr Val Glu Pro Ala
 335 340 345 350

tog ccc acc oct gcc cat agc ctg cct cgt gcc aag tog gag ctg acc 1104
 Ser Pro Thr Pro Ala His Ser Leu Pro Arg Ala Lys Ser Glu Leu Thr

16/23

355	360	365	
cta acc cca gac cca gcc ccg ccc atg gcc cac tca ccc ctg cat cgt			1152
Leu Thr Pro Asp Pro Ala Pro Pro Met Ala His Ser Pro Leu His Arg			
370	375	380	
tot gtg tct gac ctg cct ctt ccc ctg ccc cag cct gcc ctg gcc tot			1200
Ser Val Ser Asp Leu Pro Leu Pro Leu Pro Gln Pro Ala Leu Ala Ser			
385	390	395	
cct ggc tcg cca gaa ccc ctg ccc atc ctg tcc ctc aac ggt ggg ggc			1248
Pro Gly Ser Pro Glu Pro Leu Pro Ile Leu Ser Leu Asn Gly Gly Gly			
400	405	410	
cca gag ctg gct ggg gac tgg ggt ggg gct ggg gat gct ccg ctg tcc			1296
Pro Glu Leu Ala Gly Asp Trp Gly Gly Ala Gly Asp Ala Pro Leu Ser			
415	420	425	430
ccg gac cca ctg ctg tct tca cct cct ggc tct ccc aag gca gct cta			1344
Pro Asp Pro Leu Leu Ser Ser Pro Pro Gly Ser Pro Lys Ala Ala Leu			
435	440	445	
cac tca ccc gtc tcc gaa ggg gcc ccc gta att ccc cca tcc tct ggg			1392
His Ser Pro Val Ser Glu Gly Ala Pro Val Ile Pro Pro Ser Ser Gly			
450	455	460	
ctc cca ctt ccc acc cct gat gcc cgg gta ggg gcc tcc acc tgc ggc			1440
Leu Pro Leu Pro Thr Pro Asp Ala Arg Val Gly Ala Ser Thr Cys Gly			
465	470	475	
ccg ccc gac cac ctg ctg cct ccg ctg ggc acc ccg ctg ccc cca gac			1488
Pro Pro Asp His Leu Leu Pro Pro Leu Gly Thr Pro Leu Pro Pro Asp			
480	485	490	
tgg gtg acg ctg gag ggg gac ttt gtg ctc atg ttg gcc atc tcg ccc			1536
Trp Val Thr Leu Glu Gly Asp Phe Val Leu Met Leu Ala Ile Ser Pro			
495	500	505	510

17/23.

ago cac cta ggc gct gac ctg gtg gca gct ccg cat gcg cgc ttc gac 1584
 Ser His Leu Gly Ala Asp Leu Val Ala Ala Pro His Ala Arg Phe Asp

515

520

525

gac ggc ctg gtg cac ctg tgc tgg gtg cgt agc ggc atc tcg cgg gct 1632
 Asp Gly Leu Val His Leu Cys Trp Val Arg Ser Gly Ile Ser Arg Ala

530

535

540

gcg ctg ctg cgc ctt ttc ttg gcc atg gag cgt ggt agc cac ttc agc 1680
 Ala Leu Leu Arg Leu Phe Leu Ala Met Glu Arg Gly Ser His Phe Ser

545

550

555

ctg ggc tgt cgc cag ctg ggc tac gcc gcg gcc cgt gcc ttc cgc cta 1728
 Leu Gly Cys Pro Gln Leu Gly Tyr Ala Ala Ala Arg Ala Phe Arg Leu

560

565

570

gag ccg ctc aca cca cgc ggc gtg ctc aca gtg gac ggg gag cag gtg 1776
 Glu Pro Leu Thr Pro Arg Gly Val Leu Thr Val Asp Gly Glu Gln Val

575

580

585

590

gag tat ggg ccg cta cag gca cag atg cac cct ggc atc ggt aca ctg 1824
 Glu Tyr Gly Pro Leu Gln Ala Gln Met His Pro Gly Ile Gly Thr Leu

595

600

605

ctc act ggg cct cct ggc tgc ccg ggg cgg gag ccc tgaaactaaa 1870
 Leu Thr Gly Pro Pro Gly Cys Pro Gly Arg Glu Pro

610

615

caagcttggt acccgccggg ggcggggcct acattccaat ggggcggagc ttgagctagg 1930

gggtgtggcc tggctgctag agttgtggtg gcagggggccc tggccccgtc tcaggattgc 1990

gctcgctttc atgggaccag acgtgatgct ggaagggtggg cgtcgtcacg gttaaagaga 2050

aatgggctcg tcccgagggt agtgcctgat caatgagggc ggggcctggc gtctgatctg 2110

gggcgcgcct tacggggcag ggctcagtcc tgacgcttgc cacctgctcc taccgggcca 2170

18/23

ggatggctga gggcggagtc tattttaacg gtcgccaat gacaggacct ggaatgtact 2230

ggctggggta ggcctcagtg agtcggcggg tcaggggccg cagcctcgcc ccattccactc 2290

cggcgcctcc atttagctgg ccaatcagcc caggaggggc aggttccccg gggcgggcgc 2350

taggatttgc actaatgttc ctctccccgc 2380

<210> 14

<211> 618

<212> PRT

<213> Homo sapiens

<400> 14

Met Ala Pro Pro Pro Pro Pro Leu Ala Ala Ser Thr Pro Leu Leu His

1 5 10 15

Gly Glu Phe Gly Ser Tyr Pro Ala Arg Gly Pro Arg Phe Ala Leu Thr

20 25 30

Leu Thr Ser Gln Ala Leu His Ile Gln Arg Leu Arg Pro Lys Pro Glu

35 40 45

Ala Arg Pro Arg Gly Gly Leu Val Pro Leu Ala Glu Val Ser Gly Cys

50 55 60

Cys Thr Leu Arg Ser Arg Ser Pro Ser Asp Ser Ala Ala Tyr Phe Cys

65 70 75 80

Ile Tyr Thr Tyr Pro Arg Gly Arg Arg Gly Ala Arg Arg Arg Ala Thr

85 90 95

Arg Thr Phe Arg Ala Asp Gly Ala Ala Thr Tyr Glu Glu Asn Arg Ala

100 105 110

Glu Ala Gln Arg Trp Ala Thr Ala Leu Thr Cys Leu Leu Arg Gly Leu

115 120 125

19/23

Pro Leu Pro Gly Asp Gly Glu Ile Thr Pro Asp Leu Leu Pro Arg Pro
130 135 140

Pro Arg Leu Leu Leu Val Asn Pro Phe Gly Gly Arg Gly Leu Ala
145 150 155 160

Trp Gln Trp Cys Lys Asn His Val Leu Pro Met Ile Ser Glu Ala Gly
165 170 175

Leu Ser Phe Asn Leu Ile Gln Thr Glu Arg Gln Asn His Ala Arg Glu
180 185 190

Leu Val Gln Gly Leu Ser Leu Ser Glu Trp Asp Gly Ile Val Thr Val
195 200 205

Ser Gly Asp Gly Leu Leu His Glu Val Leu Asn Gly Leu Leu Asp Arg
210 215 220

Pro Asp Trp Glu Glu Ala Val Lys Met Pro Val Gly Ile Leu Pro Cys
225 230 235 240

Gly Ser Gly Asn Ala Leu Ala Gly Ala Val Asn Gln His Gly Gly Phe
245 250 255

Glu Pro Ala Leu Gly Leu Asp Leu Leu Leu Asn Cys Ser Leu Leu Leu
260 265 270

Cys Arg Gly Gly Gly His Pro Leu Asp Leu Leu Ser Val Thr Leu Ala
275 280 285

Ser Gly Ser Arg Cys Phe Ser Phe Leu Ser Val Ala Trp Gly Phe Val
290 295 300

Ser Asp Val Asp Ile Gln Ser Glu Arg Phe Arg Ala Leu Gly Ser Ala
305 310 315 320

Arg Phe Thr Leu Gly Thr Val Leu Gly Leu Ala Thr Leu His Thr Tyr

20/23

325	330	335
Arg Gly Arg Leu Ser Tyr Leu Pro Ala Thr Val Glu Pro Ala Ser Pro		
340	345	350
Thr Pro Ala His Ser Leu Pro Arg Ala Lys Ser Glu Leu Thr Leu Thr		
355	360	365
Pro Asp Pro Ala Pro Pro Met Ala His Ser Pro Leu His Arg Ser Val		
370	375	380
Ser Asp Leu Pro Leu Pro Leu Pro Gln Pro Ala Leu Ala Ser Pro Gly		
385	390	395
400		
Ser Pro Glu Pro Leu Pro Ile Leu Ser Leu Asn Gly Gly Gly Pro Glu		
405	410	415
Leu Ala Gly Asp Trp Gly Gly Ala Gly Asp Ala Pro Leu Ser Pro Asp		
420	425	430
Pro Leu Leu Ser Ser Pro Pro Gly Ser Pro Lys Ala Ala Leu His Ser		
435	440	445
Pro Val Ser Glu Gly Ala Pro Val Ile Pro Pro Ser Ser Gly Leu Pro		
450	455	460
Leu Pro Thr Pro Asp Ala Arg Val Gly Ala Ser Thr Cys Gly Pro Pro		
465	470	475
480		
Asp His Leu Leu Pro Pro Leu Gly Thr Pro Leu Pro Pro Asp Trp Val		
485	490	495
Thr Leu Glu Gly Asp Phe Val Leu Met Leu Ala Ile Ser Pro Ser His		
500	505	510
Leu Gly Ala Asp Leu Val Ala Ala Pro His Ala Arg Phe Asp Asp Gly		
515	520	525

21/23

Leu Val His Leu Cys Trp Val Arg Ser Gly Ile Ser Arg Ala Ala Leu
 530 535 540

Leu Arg Leu Phe Leu Ala Met Glu Arg Gly Ser His Phe Ser Leu Gly
 545 550 555 560

Cys Pro Gln Leu Gly Tyr Ala Ala Ala Arg Ala Phe Arg Leu Glu Pro
 565 570 575

Leu Thr Pro Arg Gly Val Leu Thr Val Asp Gly Glu Gln Val Glu Tyr
 580 585 590

Gly Pro Leu Gln Ala Gln Met His Pro Gly Ile Gly Thr Leu Leu Thr
 595 600 605

Gly Pro Pro Gly Cys Pro Gly Arg Glu Pro
 610 615

<210> 15

<211> 388

<212> PRT

<213> Mus musculus

<300>

<302> Molecular cloning and functional characterization of
 murine sphingosine kinase

<303> J. Biol. Chem.

<304> 273

<305> 37

<306> 23722-23728

<308> AAC61698

<400> 15

Met Trp Trp Cys Cys Val Leu Phe Val Val Glu Cys Pro Arg Gly Leu
 1 5 10 15

Leu Pro Arg Pro Cys Arg Val Leu Val Leu Leu Asn Pro Gln Gly Gly

22/23

20	25	30
Lys Gly Lys Ala Leu Gln Leu Phe Gln Ser Arg Val Gln Pro Phe Leu		
35	40	45
Glu Glu Ala Glu Ile Thr Phe Lys Leu Ile Leu Thr Glu Arg Lys Asn		
50	55	60
His Ala Arg Glu Leu Val Cys Ala Glu Glu Leu Gly His Trp Asp Ala		
65	70	75
Leu Ala Val Met Ser Gly Asp Gly Leu Met His Glu Val Val Asn Gly		
85	90	95
Leu Met Glu Arg Pro Asp Trp Glu Thr Ala Ile Gln Lys Pro Leu Cys		
100	105	110
Ser Leu Pro Gly Gly Ser Gly Asn Ala Leu Ala Ala Ser Val Asn His		
115	120	125
Tyr Ala Gly Tyr Glu Gln Val Thr Asn Glu Asp Leu Leu Ile Asn Cys		
130	135	140
Thr Leu Leu Leu Cys Arg Arg Arg Leu Ser Pro Met Asn Leu Leu Ser		
145	150	155
Leu His Thr Ala Ser Gly Leu Arg Leu Tyr Ser Val Leu Ser Leu Ser		
165	170	175
Trp Gly Phe Val Ala Asp Val Asp Leu Glu Ser Glu Lys Tyr Arg Arg		
180	185	190
Leu Gly Glu Ile Arg Phe Thr Val Gly Thr Phe Phe Arg Leu Ala Ser		
195	200	205
Leu Arg Ile Tyr Gln Gly Gln Leu Ala Tyr Leu Pro Val Gly Thr Val		
210	215	220

23/23

Ala Ser Lys Arg Pro Ala Ser Thr Leu Val Gln Lys Gly Pro Val Asp
225 230 235 240

Thr His Leu Val Pro Leu Glu Glu Pro Val Pro Ser His Trp Thr Val
245 250 255

Val Pro Glu Gln Asp Phe Val Leu Val Leu Val Leu Leu His Thr His
260 265 270

Leu Ser Ser Glu Leu Phe Ala Ala Pro Met Gly Arg Cys Glu Ala Gly
275 280 285

Val Met His Leu Phe Tyr Val Arg Ala Gly Val Ser Arg Ala Ala Leu
290 295 300

Leu Arg Leu Phe Leu Ala Met Gln Lys Gly Lys His Met Glu Leu Asp
305 310 315 320

Cys Pro Tyr Leu Val His Val Pro Val Val Ala Phe Arg Leu Glu Pro
325 330 335

Arg Ser Gln Arg Gly Val Phe Ser Val Asp Gly Glu Leu Met Val Cys
340 345 350

Glu Ala Val Gln Gly Gln Val His Pro Asn Tyr Leu Trp Met Val Cys
355 360 365

Gly Ser Arg Asp Ala Pro Ser Gly Arg Asp Ser Arg Arg Gly Pro Pro
370 375 380

Pro Glu Glu Pro
385

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/09664

A. CLASSIFICATION OF SUBJECT MATTER																				
IPC(7) : C07H 21/04; C12N 9/12, 15/63, 5/00, 5/04, 5/06, 1/20, 1/16; C12P 21/06; C12Q 1/48; G01N 33/53; A61K 38/45, 39/395, 31/70																				
US CL : 536/23.2; 435/194, 320.1, 325, 419, 252.3, 254.11, 69.1, 15, 7.1, 6; 424/94.5, 139.1; 514/44																				
B. FIELDS SEARCHED																				
Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/23.2; 435/194, 320.1, 325, 419, 252.3, 254.11, 69.1, 15, 7.1, 6; 424/94.5, 139.1; 514/44																				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE, AGRICOLA, CAPLUS, BIOSIS, EMBASE, WIPDS, PROMT, GENBANK, EMBL																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
P, Y	LIU et al. Molecular Cloning and Functional Characterization of a Novel Mammalian Sphingosine Kinase Type 2 Isoform J. Biol. Chem. June 2000, Vol 275. No. 26, pages 19513-19520.	1-13, 15, 16, 18, 19, 21, 22, 24-26																		
A	OLIVERA et al. Sphingosine Kinase: A Mediator of Vital Cellular Functions Prostaglandins April 2001, Vol 64. No. 1-4, pages 123-134.	1-13, 15, 16, 18, 19, 21, 22, 24-26																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td colspan="2">* Special categories of cited documents:</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td></td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"E" earlier application or patent published on or after the international filing date</td> <td></td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td></td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance		"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E" earlier application or patent published on or after the international filing date		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		"&" document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means			"P" document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
"A" document defining the general state of the art which is not considered to be of particular relevance		"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
"E" earlier application or patent published on or after the international filing date		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		"&" document member of the same patent family																		
"O" document referring to an oral disclosure, use, exhibition or other means																				
"P" document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 03 August 2001 (03.08.2001)		Date of mailing of the international search report 19 SEP 2001																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230		Authorized officer David J. Steadman Telephone No. (703) 308-0196																		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/09664

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.